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ABSTRACT 
Background. Human papillomavirus (HPV) is, in addition to smoking and alcohol, a risk 
factor for developing oropharyngeal squamous cell carcinoma (OPSCC), and more 
specifically tonsillar- and base of tongue squamous cell carcinoma (TSCC & BOTSCC 
respectively). Interestingly, HPV-positive (HPV+) TSCC/BOTSCC has a remarkably better 
clinical outcome than HPV-negative (HPV-) TSCC/BOTSCC and head and neck cancer in 
general. However, the role of HPV and other biomarkers in cancer of unknown primary in the 
head and neck region (HNCUP), i.e. where only a lymph node metastasis and no primary 
tumour is found, is not well understood. Moreover, the genetic landscape of HPV-positive 
HNCUP and the prognostic implications of certain mutations in TSCC/BOTSCC has not 
been studied extensively. Furthermore, using fine-needle aspiration cytology (FNAC) from 
neck masses for HPV-detection and potentially for predicting an HPV-positive 
TSCC/BOTSCC as the final diagnosis would be highly clinically useful, but has not been 
studied prospectively in a cohort consisting of both malignant and benign neck masses. 
Aims. To investigate HPV DNA and mRNA and other prognostic biomarkers (p16, p53, 
CD8+ tumour infiltrating lymphocytes (TILs), HLA Class I expression) in HNCUP in 
relation to clinical outcome. Moreover, to study mutations in HPV+ HNCUP and 
TSCC/BOTSCC in relation to prognosis and to analyse whether HPV-detection in FNAC 
from neck masses is reliable and if a finding of HPV could predict an HPV+ TSCC/BOTSCC 
as the final diagnosis. 
Results. In Paper I, we show that HPV is a favourable prognostic factor in HNCUP, and in 
Paper II, we validate this finding in a separate cohort (3-year overall survival 86% vs. 54% 
for HPV+ and HPV- HNCUP respectively, in the combined cohorts). In Paper II, we also 
demonstrate that HPV mRNA is expressed in the vast majority of HPV DNA+ HNCUP. 
Moreover, in Paper I we find that high p53-expression correlates to a poor prognosis, and in 
Paper II that a low number of CD8+ TILs are potentially related to a poor outcome, while 
HLA Class I expression does not appear to be a prognostic factor in HNCUP. In Paper III, we 
show that TP53, CDKN2A and PIK3CA are the most commonly mutated genes in HPV+ 
HNCUP, and that having a mutation in FGFR3 correlated to a poor prognosis in HPV+ 
TSCC/BOTSCC. In Paper IV, we demonstrate that HPV DNA detection in FNAC from neck 
masses of unknown origin is reliable and could be used prospectively to predict an HPV+ 
TSCC/BOTSCC as the final diagnosis. HPV DNA was not found in malignant conditions 
other than HPV+ TSCC/BOTSCC or in any benign conditions, including branchial cleft 
cysts. 
Conclusions. HPV appears to have a similar causative and prognostic role in HNCUP as in 
TSCC/BOTSCC. Investigation of HPV-status should therefore be part of the diagnostic 
work-up of an HNCUP. Examination of HPV DNA-status using FNAC is useful in the 
clinical investigation of patients with neck masses of unknown origins, including patients 
eventually diagnosed with HNCUP or TSCC/BOTSCC.  
LIST OF SCIENTIFIC PAPERS INCLUDED IN THE THESIS 
I. Sivars L, Näsman A, Tertipis N, Vlastos A, Ramqvist T, Dalianis T, Munck-
Wikland E, Nordemar S. Human papillomavirus and p53 expression in 
cancer of unknown primary in the head and neck region in relation to clinical 
outcome. Cancer Med. 2014 Apr;3(2):376-84. 
 
II. Sivars L, Landin D, Grün N, Vlastos A, Marklund L, Nordemar S, Ramqvist 
T, Munck-Wikland E, Näsman A, Dalianis T. Validation of human 
papillomavirus as a favourable prognostic marker and analysis of CD8+ 
tumour-infiltrating lymphocytes and other biomarkers in cancer of unknown 
primary in the head and neck region. Anticancer Res. 2017 Feb;37(2):665-
673. 
 
III. Bersani C, Sivars L, Haeggblom L, DiLorenzo S, Mints M, Ährlund-Richter 
A, Tertipis N, Munck-Wikland E, Näsman A, Ramqvist T, Dalianis T. 
Targeted sequencing of tonsillar and base of tongue cancer and human 
papillomavirus positive unknown primary of the head and neck reveals 
prognostic effects of mutated FGFR3. Oncotarget. 2017 May 
23;8(21):35339-35350. 
 
IV. Sivars L*, Landin D*, Haeggblom L, Tertipis N, Grün N, Bersani C, 
Marklund L, Ghaderi M, Näsman A, Ramqvist T, Nordfors C*, Munck-
Wikland E*, Tani E*, Dalianis T*. Human papillomavirus DNA detection in 
fine-needle aspirates as indicator of human papillomavirus-positive 
oropharyngeal squamous cell carcinoma: A prospective study. Head Neck. 
2017 Mar;39(3):419-426. 
 
 
*Contributed equally 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RELATED PUBLICATIONS, NOT INCLUDED IN 
THE THESIS 
I. Nordfors C, Grün N, Tertipis N, Ährlund-Richter A, Haeggblom L, 
Sivars L, Du J, Nyberg T, Marklund L, Munck-Wikland E, Näsman 
A, Ramqvist T, Dalianis T. CD8+ and CD4+ tumour infiltrating 
lymphocytes in relation to human papillomavirus status and clinical 
outcome in tonsillar and base of tongue squamous cell carcinoma. 
Eur J Cancer. 2013 Jul;49(11):2522-30. 
 
II. Nordfors C, Grün N, Haeggblom L, Tertipis N, Sivars L, Mattebo 
M, Larsson M, Häggström-Nordin E, Tydén T, Ramqvist T, 
Dalianis T. Oral human papillomavirus prevalence in high school 
students of one municipality in Sweden. Scand J Infect Dis. 2013 
Nov;45(11):878-81. 
  
III. Sivars L, Tertipis N, Näsman A, Ramqvist T, Dalianis T (2014) A 
simple approach for determining presence of HPV DNA from slides 
previously stained for P16ink4a. J Cytol Histol S4:014. 
 
IV. Tertipis N, Hammar U, Näsman A, Vlastos A, Nordfors C, Grün N, 
Ährlund-Richter A, Sivars L, Haeggblom L, Marklund L, 
Hammarstedt-Nordenvall L, Chaturvedi AK, Munck-Wikland E, 
Ramqvist T, Bottai M, Dalianis T. A model for predicting clinical 
outcome in patients with human papillomavirus-positive tonsillar 
and base of tongue cancer. Eur J Cancer. 2015 Aug;51(12):1580-7. 
 
V. Sivars L, Tani E, Näsman A, Ramqvist T, Munck-Wikland E, 
Dalianis T. Human papillomavirus as a diagnostic and prognostic 
tool in cancer of unknown primary in the head and Neck region. 
Anticancer Res. 2016 Feb;36(2):487-93. (Review) 
 
VI. Sivars L, Bersani C, Grün N, Ramqvist T, Munck-Wikland E, Von 
Buchwald C, Dalianis T. Human papillomavirus is a favourable 
prognostic factor in cancer of unknown primary in the head and 
neck region and in hypopharyngeal cancer. Mol Clin Oncol. 2016 
Dec;5(6):671-674. (Review) 
 
VII. Bersani C, Mints M, Tertipis N, Haeggblom L, Sivars L, Ährlund-
Richter A, Vlastos A, Nordfors N, Grün N, Munck-Wikland E, 
Näsman A, Ramqvist T, Dalianis T. A model using four 
concomitant biomarkers for predicting outcome in patients with 
human papillomavirus positive tonsillar and base of tongue 
squamous cell carcinoma. Oral Oncol. 2017 May;68:53-59 
 
VIII. Sivars L, Landin D, Rizzo M, Haeggblom L, Bersani C, Munck-
Wikland E, Dalianis T, Näsman A, Marklund L. Presence of 
Human papillomavirus (HPV) in branchial cleft cysts – a way to 
distinguish branchial cleft cysts from cystic metastases? (Submitted) 
TABLE OF CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Infections and cancer ............................................................................................. 1 
1.2 Human papillomavirus (HPV) .............................................................................. 3 
1.2.1 General background .................................................................................. 3 
1.2.2 Viral particle and the HPV-genome ......................................................... 3 
1.2.3 Classification ............................................................................................. 4 
1.2.4 Viral life cycle and carcinogenesis ........................................................... 4 
1.2.5 HPV in cancer and preventive measures .................................................. 7 
1.3 Head and neck cancer, oropharyngeal cancer and other conditions causing 
neck masses ........................................................................................................... 8 
1.3.1 General background on head and neck cancer ......................................... 8 
1.3.2 Oropharyngeal squamous cell carcinoma (OPSCC) ................................ 9 
1.3.3 Cancer of unknown primary in the head and neck region 
(HNCUP) ................................................................................................. 10 
1.3.4 Benign conditions causing neck masses ................................................. 11 
1.4 Diagnostic procedures of head and neck masses ................................................ 12 
1.4.1 Head and neck cancer including oropharyngeal squamous cell 
carcinoma ................................................................................................ 12 
1.4.2 Cancer of unknown primary in the head and neck region ..................... 13 
1.4.3 Branchial cleft cysts ................................................................................ 13 
1.4.4 HPV-detection in fine-needle aspirates from neck masses .................... 14 
1.5 Treatment of head and neck masses ................................................................... 15 
1.5.1 Head and neck cancer ............................................................................. 15 
1.5.2 Oropharyngeal squamous cell carcinomas ............................................. 15 
1.5.3 Cancer of unknown primary in the head and neck region ..................... 15 
1.5.4 Branchial cleft cysts ................................................................................ 16 
1.6 Reflections on personalized treatment in HNCUP, OPSCC and branchial 
cleft cysts ............................................................................................................. 16 
1.7 Unanswered questions at the time when this thesis project was initiated ......... 18 
2 Aims ............................................................................................................................... 19 
3 Study subjects, material and methods ........................................................................... 20 
3.1 General introduction to methods of HPV-detection in HNSCC ........................ 20 
3.2 Study subjects and patient material..................................................................... 21 
3.3 Methods ............................................................................................................... 22 
3.3.1 HPV DNA and RNA extraction ............................................................. 22 
3.3.2 HPV DNA and RNA detection ............................................................... 23 
3.3.3 Immunohistochemistry (IHC) ................................................................. 24 
3.3.4 Sequencing .............................................................................................. 26 
3.3.5 Statistical methods .................................................................................. 27 
4 Results and discussion ................................................................................................... 28 
  
4.1 Human papillomavirus and p53 expression in cancer of unknown primary 
in the head and neck region in relation to clinical outcome. (Paper I) .............. 28 
4.2 Validation of Human Papillomavirus as a Favourable Prognostic Marker 
and Analysis of CD8+ Tumour-infiltrating Lymphocytes and Other 
Biomarkers in Cancer of Unknown Primary in the Head and Neck 
Region. (Paper II) ................................................................................................ 30 
4.3 Targeted sequencing of tonsillar and base of tongue cancer and human 
papillomavirus positive unknown primary of the head and neck reveals 
prognostic effects of mutated FGFR3. (Paper III) .............................................. 32 
4.4 Human papillomavirus DNA detection in fine-needle aspirates as 
indicator of human papillomavirus-positive oropharyngeal squamous cell 
carcinoma: A prospective study. (Paper IV)....................................................... 35 
5 Conclusions ................................................................................................................... 38 
6 Future perspectives ........................................................................................................ 39 
7 Acknowledgements ....................................................................................................... 41 
8 References ..................................................................................................................... 43 
 
  
LIST OF ABBREVIATIONS 
  
ADC Adenocarcinomas 
BCC Branchial cleft cyst 
BOTSCC Base of tongue squamous cell carcinoma 
BSGP Broad spectrum general primer 
CD Cluster of differentiation 
CUP Cancer of unknown primary 
CT Computed tomography 
DFS Disease-free survival 
E Early region 
EBV Epstein-Barr virus 
EV Epidermodysplasia verucciformis 
E6AP E6 associated protein 
FFPE Formalin-fixed paraffin-embedded 
FISH Fluorescent in-situ hybridization 
FNAC Fine-needle aspiration cytology 
GP General primer 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HHV Human herpes virus 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HNC Head and neck cancer 
HNCUP Head and neck cancer of unknown primary 
HNSCC Head and neck squamous cell carcinoma 
HPV Human papillomavirus 
HR High risk 
hTERT Human telomerase reverse transcriptase 
HTLV-1 Human T-lymphotropic virus-1 
IARC International agency for research on cancer 
  
ICD-10 International statistical classification of diseases and related 
health problems - tenth revision 
IHC Immunohistochemistry 
ISH In situ hybridization 
KSHV Kaposi’s sarcoma herpes virus 
L Late region 
LCR Long control region 
LR Low risk 
MCV Merkel cell polyomavirus 
MRI Magnetic resonance imaging 
MFI Median fluorescence intensity 
mRNA Messenger ribonucleic acid 
NGS Next generation sequencing 
OPSCC Oropharyngeal squamous cell carcinoma 
OS Overall survival 
PAD Pathological anatomical diagnosis 
PCR Polymerase chain reaction 
PET Positron-emission tomography 
pRb Retinoblastoma protein 
RT Radiotherapy 
SCC Squamous cell carcinoma 
TIL Tumour infiltrating lymphocyte 
TSCC Tonsillar squamous cell carcinoma 
TSS Tumour specific survival 
 
  1 
1 INTRODUCTION 
 
1.1 INFECTIONS AND CANCER 
Of the 14 million annual new cancer cases, worldwide, approximately 2.2 million or 15.4% 
are attributable to infectious agents, thus making pathogens one of the most common causes 
of cancer. This is especially true in the less developed part of the world where the percentage 
of tumours caused by infections are much greater than in developed countries, ranging from 
31.3% in Sub-Saharan Africa to 7% in Europe and 4% in North America (Plummer et al., 
2016).  
High-risk human papillomavirus (HPV), Hepatitis B- and C-virus (HBV & HCV, 
respectively), Epstein-Barr virus (EBV) and the bacteria Helicobacter pylori are the most 
frequent pathogens associated with cancer, but additional viruses as well as a few trematodes 
have been shown to be able to cause cancer in humans. A list of biological agents recognized 
as carcinogenic by the International Agency for Research on Cancer (IARC) and others; the 
types of cancer they are linked to; and approximate number of new cases per year and agent 
are depicted in Table 1 (IARC Monograph, 2012; Plummer et al., 2016; Schadendorf et al., 
2017). In addition, human immunodeficiency virus (HIV) is sometimes recognized as a 
tumour virus, although HIV does not have a direct carcinogenic effect, but rather sets the 
stage for other infectious agents through its immune suppressive effects (Moore et al., 2010). 
That cancer can be caused by a transmissible agent was suspected as early as in the 1840’s 
when the Italian physician Rigoni-Stern investigated death certificates of women in Verona 
and noticed that cancer of the uterine cervix was more common in married women, widows 
and prostitutes than in nuns, thus leading to the hypothesis that a sexually transmissible agent 
caused cervical cancer (Rigoni-Stern, 1842; zur Hausen, 2009). Evidence that small 
transmissible agents, could indeed cause cancer, was provided by Francis Peyton Rous in his 
famous experiment with hens in 1909 for which he later was awarded the Nobel Prize in 
physiology or medicine. In the seminal experiment, Rous resected a sarcomatous chest 
tumour from a hen, grinded and filtered it thoroughly and injected the resulting extract into 
another hen, which then developed a similar chest tumour (Rous, 1910; Rous, 1911). In 1964, 
the first human tumour virus – EBV, was discovered in Burkitt’s lymphoma cell lines 
(Epstein et al., 1964). So far, another six human tumour viruses have been described (see 
Table 1), in addition to a number of viruses causing cancer in other species. In 1983, high-
risk HPV types were discovered in cervical cancer (Durst et al., 1983), finding the 
transmissible agent the Rigoni-Sterns study had hinted about, and landing Harald zur Hausen 
the Nobel Prize in 2008 (Moore et al., 2010). 
It has been suggested that infectious cancer agents can be broadly categorized into two 
groups, either causing cancer in a direct way or in an indirect way. In the direct way, the 
agent, typically a virus is present in each cell and produces oncogenes that directly contribute 
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to the carcinogenesis and maintains the transformed tumour cell phenotype. HPV, Merkel 
Cell polyomavirus (MCV), EBV and Kaposi’s sarcoma herpes virus (KSHV) induce and 
maintain neoplasms in this way (Moore et al., 2010). The produced oncogenes often target 
pRb (thus increasing cell cycle progression allowing for replication of the viral genomes) and 
p53 (e.g. inhibiting apoptosis) leading to transformation of host cells. Indirect carcinogens, 
e.g. H. pylori, are proposed to cause cancer by inducing persistent infection & inflammation 
with subsequent increased cell division leading to eventual mutations and transformation of 
the cells. However, the categorization into direct or indirect carcinogens may be an 
oversimplification, as several agents, e.g. HBV, HCV & Human T-lymphotropic virus-1 
(HTLV-1) cannot be categorized into either of these categories, producing both potentially 
oncogenic proteins and causing persistent inflammation (Moore et al., 2010). 
 
Table 1. Infectious agents causing cancer in humans, the cancer types they are associated 
with and the estimated number of new cancer cases each agent is associated with worldwide 
per year (IARC Monograph 100b. 2012; Plummer et al., 2016; Schadendorf et al., 2017). 
Pathogen Type Associated cancer types Approx. no. 
cases/year 
worldwide 
Clonorchis sinensis Trematode Cholangiocarcinoma 1.300* 
Epstein-Barr virus (EBV), 
also known as human 
herpesvirus 4 (HHV4) 
Herpesvirus Nasopharyngeal carcinoma 
Lymphomas 
120.000 
Helicobacter pylori Bacteria Gastric carcinoma 
Gastric lymphomas 
770.000 
Hepatitis B virus (HBV) Hepadnavirus Hepatocellular carcinoma 420.000 
Hepatitis C virus (HCV) Flavivirus Hepatocellular carcinoma 
Lymphomas 
170.000 
High-risk human 
papillomavirus (HPV) 
Papillomavirus Cervical cancer 
Anogenital cancer 
Head & neck cancer 
640.000 
Human T-lymphotropic 
virus-1 (HTLV-1) 
Retrovirus Adult T-cell leukemia 3.000 
Kaposi’s sarcoma 
herpesvirus (KSHV), also 
known as human herpesvirus 
8 (HHV8) 
Herpesvirus Kaposi’s sarcoma 
Primary effusion 
lymphoma 
44.000 
Merkel cell polyomavirus 
(MCV) 
Polyomavirus Merkel cell carcinoma 1.500** 
Opisthorchis viverrini Trematode Cholangiocarcinoma 1.300* 
Schistosoma haematobium Trematode Bladder carcinoma 7.000 
*Number denotes cancer attributable to infection by any of the two liver flukes. ** Number 
denotes cases of Merkel Cell carcinoma in the United States 2008. No worldwide calculations 
available. 
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A point worth noting is that cancer development following infection with any of the above-
mentioned agents should be regarded as biological accidents. The pathogen does not gain any 
evolutionary advantages by causing cancer, e.g. it does not increase transmission or viral 
burden. Carcinogenesis is rather an unwanted side effect of the pathogens strategy to carrying 
out its life cycle and replicate or to evade the host immune system (Moore et al., 2010). 
After this brief introduction to infections & cancer in general, the rest of the thesis will focus 
on HPV with special attention given to its role in head & neck cancer, oropharyngeal cancer, 
tonsillar and base of tongue cancer and most specifically cancer of unknown primary of the 
head and neck region (HNCUP).   
1.2 HUMAN PAPILLOMAVIRUS (HPV) 
1.2.1 General background 
There are more than 200 different types of HPV, which can be divided into high risk (HR) 
and low risk (LR) types depending on their ability to induce tumours (Papillomavirus 
Episteme, NIH, 2017; Tommasino, 2014). High risk types can give rise to e.g. cervical- and 
anogenital cancers as well as subsets of head and neck squamous cell carcinomas (HNSCC). 
The International Agency for Research on Cancer (IARC)/World Health Organization 
(WHO) are currently listing 12 HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 
59) as carcinogenic in humans with another 13 as putative carcinogens (IARC Monograph 
100b, 2012). The most frequent HR types causing cervical cancer, accounting for 
approximately 70% of the cases, are HPV16 and HPV18, while HPV16 alone stands for > 
80% of HPV+ HNSCC and > 90% of HPV+ tonsillar squamous cell carcinoma (TSCC) and 
base of tongue squamous cell carcinoma (BOTSCC) (de San Jose et al., 2010; Ndiaye et al., 
2014). The low risk types can give rise to a number of conditions including genital warts (e.g. 
HPV6 & 11), common skin warts (e.g. HPV1 & 2) and recurrent respiratory papillomatosis 
(e.g. HPV6 & 11) (Tommasino, 2014). However, under certain circumstances, such as in 
immunocompromised individuals, or in patients with certain conditions such as 
epidermodysplasia verucciformis (EV) some cutaneous LR HPV-types (e.g. HPV5 and 8) 
have been implicated in cancer development as well (Tommasino, 2014). Below, first the 
molecular and then the clinical aspects of HPV infection will be discussed in greater detail. 
1.2.2 Viral particle and the HPV-genome 
All HPV types are small (55 nm in diameter) with an icosahedral capsid and a circular 
double-stranded DNA genome of approximately 8000 base pairs (Tommasino, 2014). The 
genome consists of an early region (E), a late region (L) and a long control region (LCR), the 
latter containing regulatory elements (Tommasino, 2014). There are six regulatory proteins 
(E1, E2, E4-E7) involved in various steps in the viral life cycle, and two structural proteins, 
the major (L1) and minor (L2) capsid proteins (Tommasino, 2014). See Figure 1 for a 
schematic representation. The proteins and their involvement in the viral life cycle are 
described in more detail further down with a special focus on E6 & E7 – the two most 
important proteins involved in HPV-induced carcinogenesis (Moody & Laimins, 2010). 
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Figure 1. Schematic representation of the organization of the human papillomavirus 16 
genome, and the major functions of the viral proteins. LCR = Long control region. P97 and 
P670 = the early and late promotors respectively. (Tommasino, 2014; with permission from 
publisher). 
1.2.3 Classification 
HPVs are classified according to the homology of the well-conserved L1 gene, as determined 
by whole gene sequencing. Human papillomaviruses belong to one of five genera (Alpha-, 
Beta-, Gamma-, Mu- and Nu-papillomaviruses) with types within one genus typically 
showing less than 60% homology of the L1 region to that of other genera (Bernard et al., 
2010). They are further divided into species and then types with more than 200 different 
types sequenced in full so far (Papillomavirus Episteme, NIH, 2017). Each type is at least 
10% different in its L1 nucleotide sequence compared to all other types (Bernard et al., 
2010). The different genera and types show differences in behaviour and are associated with 
different diseases infecting either mucosal or cutaneous epithelia. The high-risk types belong 
to the Alpha-species, although the Alpha-species include mucosal LR (e.g. HPV6 & 11) and 
cutaneous HPV-types as well (Tommasino, 2014). The Beta- and Gammatypes are cutaneous 
with the Betatypes being implicated in squamous cell carcinoma (SCC) of EV- and other 
immunocomprised individuals, while the Mu types are cutaneous benign (Tommasino, 2014). 
Below, the focus will be on the mucosal high-risk types, especially HPV16, which is the most 
well studied HPV-type. 
1.2.4 Viral life cycle and carcinogenesis 
HR HPVs are sexually transmitted and carry out their life cycle in mucosal epithelia, where 
they infect the cells in the basal layer. It has been suggested that micro wounds in the 
epithelium and the subsequent wound healing response facilitates a successful infection. 
Infection may then be cleared by the host immune response (usually within 6-12 months) or 
in a small number of cases, result in an asymptomatic carrier state, which then later may 
result in neoplasia. HPV gains entry to the keratinocytes in a complex and poorly understood  
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Figure 2. Life cycle of high-risk HPVs and expression patterns of the different viral proteins 
in cervical epithelium (Doorbar, 2012; with permission from publisher). 
 
fashion involving L1 and L2 and heparan sulfate proteoglycans on the basement membrane 
and on the basal cells themselves. It then enters the cells by endocytosis and the virions are 
transported to the nucleus, where the HPV DNA can then either exist in an episomal, non-
integrated, form, or become integrated into the host genome. The HPV life cycle is thereafter 
tightly linked to the maturation of the keratinocytes. See Figure 2 for a schematic picture of 
the life cycle of HR HPV and expression of the various HPV proteins in cervical epithelium 
(Doorbar, 2012). 
Upon persistent infection, HR HPV can cause tumour development. The viral contribution to 
the carcinogenesis is complex and below only the most central mechanisms will be presented, 
see also Figure 3. The two most important HPV-proteins involved in carcinogenesis are E6 
and E7 and continuous expression of these proteins is necessary for maintaining a malignant 
phenotype (Tommasino, 2014).  
E6 binds to the E6-associated protein (E6AP). The resulting E6/E6AP-complex then binds to 
the core domain of p53 leading to rapid ubiquitination of p53, thus targeting it for 
degradation in the proteasome (Moody & Laimins, 2010). Hence, in HPV-induced cancers, 
p53 is dysregulated at the protein level rather than mutated as in many other tumour types 
(O´Sullivan et al., 2015). The transcription factor p53 is one of the most important tumour 
suppressor genes with many functions, e.g. to halt the cell cycle in case of cellular stress, thus 
giving the cell time to repair any DNA-damage. If this is not possible, p53 can induce 
apoptosis (Hanahan & Weinberg, 2011). Cells infected with HR HPV, thus lose important 
cell cycle control mechanisms and effective DNA-repair leading to cell division despite 
mutations or DNA damage, and this way eventually also may develop a malignant 
phenotype. Furthermore, the E6/E6AP-complex is also involved in transcriptional activation 
of the human telomerase reverse transcriptase (hTERT) gene coding for a subunit of the 
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telomerase complex, allowing for increased telomerase activity in HR HPV infected cells. 
This helps the cells to maintain telomere length and proliferate indefinitely without entering a 
state of replicative senescence (Moody & Laimins. 2010). 
E7 binds to the Retinoblastoma protein (pRb), another important tumour suppressor, and its 
related proteins p107 and p130, all three involved in cell cycle control. pRb controls the entry 
of cells into the S-phase of the cell cycle. Active, hypophosphorylated, pRb binds to and 
inhibits members of the E2F family of transcription factors, which activate genes necessary 
for DNA synthesis. Binding of E7 leads to degradation of pRb through proteasomal 
pathways. E2F is released when pRb is lost, which leads to the promotion of cell cycle 
progression and transformational properties in cells infected with HR HPVs. Theoretically, 
loss of pRb would lead to p53 mediated cell growth inhibition and apoptosis if the cells 
would still have functional p53. This explains why HR HPVs have developed strategies 
targeting both p53 (with E6) and pRb (with E7) to promote proliferation. LR HPV E7 also 
binds to pRb, but with less affinity (Moody & Laimins, 2010). Down regulation of pRb also 
leads to up regulation of the p16 protein, and p16 overexpression is therefore often used as a 
surrogate marker for HPV-induced HNSCC (Venuti & Paolini, 2012).   
E5 is also considered to contribute to tumour development, e.g. by stimulating the mitogenic 
signals of growth factors (Tommasino, 2014). E5 has furthermore been reported to down-
regulate human leukocyte antigen (HLA)-Class I expression on the surface of cells, and thus 
help HPV-infected cells to avoid detection by the host immune system (Campo et al., 2010).  
The other HPV-proteins have lesser roles in tumour development. E1 and E2 are e.g. 
involved in controlling viral replication (Tommasino, 2014). Loss of E2 upon viral 
integration into the host genome, leads to increased transcription of E6 and E7 (Moody & 
Laimins, 2012). E4 has been suggested to be involved in viral particle release. L1 is the major 
capsid protein, can self-assemble into virus like particles and is the major component of the 
prophylactic HPV-vaccines, while L2 is the minor capsid protein (Tommasino, 2014), see 
also Figure 1. 
After this introduction to the more molecular aspects of HPVs involvement in cancer, we will 
in the next section turn our attention towards more clinical and epidemiological features. 
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Figure 3. HPV E6 and E7 and their contributions to carcinogenesis (Tommasino, 2014; with 
permission from publisher). 
 
1.2.5 HPV in cancer and preventive measures 
HR HPVs have been estimated to cause of almost all of the 530 000 cases of cancer of the 
uterine cervix worldwide per year (Plummer et al., 2016). HPV16 and 18 dominate and stand 
for approximately 70% of the cases of invasive cervical cancer, while HPV16, 18 or 45 
together are found in 94% of the cervical adenocarcinomas (de San Jose et al., 2010). In 
addition, HR HPVs are indicated to be the cause of ~51% of penile carcinomas, 88% of anal 
carcinomas, 78% of vaginal carcinomas and 15-48% of vulvar carcinomas (depending on the 
age of the patient, with higher prevalence among younger women) worldwide (Plummer et 
al., 2016). HR HPVs are also the cause of certain subsets of HNSCC and these will be 
described below. In total, HR HPVs are estimated to cause approximately 640 000 cases of 
cancer per year, adding up to 4.6% of all cancer cases (Plummer et al., 2016). HR HPVs are 
thus important carcinogens and significant resources have been allocated to prevent HPV-
related cancers. Preventive measures consisted in the past decades of screening for cervical 
cancer when available, and more recently of preventive HPV vaccination. 
For cervical cancer, in many countries, there are screening programs for precursor lesions in 
cytology samples and/or for HR HPVs. For TSCC or BOTSCC however, there are no 
screening programs available, since there are no established precursor lesions for TSCC or 
BOTSCC, as is the case with cervical intraepithelial neoplasia (CIN) in cervical cancer.  
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Today, prophylactic HPV-vaccines are based on self-assembled L1 proteins, which form 
virus like particles. Gardasil (Merck, USA), approved by the US Food and Drug 
Administration (FDA) in 2007 covers HR HPV types 16 and 18 as well as LR types 6 and 11, 
responsible for causing genital warts, while Cervarix (Glaxo-SmithKline, UK), FDA 
approved shortly thereafter, only covers HPV 16 and 18 (O’Sullivan et al., 2015). Recently, a 
nona-valent vaccine – Gardasil 9 (Merck, USA), covering HPV-types 6, 11, 16, 18, 31, 33, 
45, 52 and 58 has been introduced (Drolet et al., 2014). The studies behind the introduction of 
these vaccines, showing very good efficacy and few side effects, have been performed in 
cervical cancer (Villa et al., 2005; Villa et al., 2006; FUTURE II Study Group, 2007). The 
vaccines have however also been suggested to be effective for preventing other HR HPV-
induced tumours, e.g. HPV-positive TSCC and BOTSCC. Programs for vaccinating girls 
have been started in many countries and a few countries, e.g. Australia, have also started to 
vaccinate boys, something currently being discussed in Sweden (Ali et al., 2017; 
Folkhälsomyndigheten, 2017). 
 
1.3 HEAD AND NECK CANCER, OROPHARYNGEAL CANCER AND OTHER 
CONDITIONS CAUSING NECK MASSES 
1.3.1 General background on head and neck cancer 
The term head and neck cancer (HNC) includes cancer of e.g. the larynx, the hypopharynx, 
the oropharynx, the nasopharynx, the oral- and nasal cavities and salivary glands as well as 
cancers of unknown primary in the head and neck region (O´Sullivan et al., 2015). It is the 
6th most common form of cancer in the world with ~600.000 cases per year and a mortality 
rate of ~50% (Ferlay et al., 2008). However, it is less frequent in the developed world with 
e.g. approximately 1300 cases per year in Sweden (Nationellt vårdprogram, Huvud- och 
Halscancer, 2015). The great majority of HNC cases (80-90%) are squamous cell carcinomas 
(HNSCC) (Nationellt vårdprogram, Huvud- och Halscancer, 2015), of which oropharyngeal 
squamous cell carcinoma (OPSCC) and cancer of unknown primary (HNCUP) will be 
discussed more, while e.g. adenocarcinomas, salivary gland tumours or lymphomas will not 
be presented in detail. 
It has long been established that smoking and alcohol are common risk factors for HNSCC 
(Wenig, 2016). Additionally, in 2007, HR type HPV16 was added to the list as a causative 
agent for OPSCC and more specifically TSCC, by the International Agency for Research on 
Cancer (IARC) (IARC-Monographs, 2007). Other causes of HNSCC include e.g. bethel nut 
chewing, poor mouth hygiene, and certain smokeless tobaccos, although Swedish “snus” has 
not been linked to HNSCC (Luo et al., 2008; O´Sullivan et al., 2015). 
There are some studies characterizing the genomic landscape of HNSCC. The Cancer 
Genome Atlas (TCGA) includes e.g. whole exome sequencing by next generation sequencing 
(NGS) of 279 flash-frozen HNSCC - 172 from the oral cavity, 72 from laryngeal sites, 2 from 
the hypopharynx and 33 OPSCC (Cancer Genome Atlas Network, 2015). The 36 HPV-
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positive tumours had frequent activating mutations of PIK3CA, an oncogene implicated in 
e.g. cervical cancer. Loss of TRAF3, encoding a protein involved in antiviral immune 
response, and where the loss leads to abnormal NF-kB signalling was also found in HPV 
positive tumours. Furthermore, amplification of E2F1, which encodes a transcription factor 
important for the cell cycle was also frequently seen (Cancer Genome Atlas Network, 2015).  
Almost all smoking related tumours showed loss of function mutations in TP53 and 
inactivation of CDKN2A, which encodes p16, while these alterations were very rare in HPV-
positive tumours (Cancer Genome Atlas Network, 2015). Patients with HPV-positive 
tumours and, interestingly, HPV-negative tumours with wild type TP53 had better survival 
than HPV-negative, TP53-mutated tumours (Cancer Genome Atlas Network, 2015). 
In another study, Chung et al. (2015), showed that using FFPE tumours was comparable to 
using fresh frozen tissue when performing NGS in HNSCC, allowing comprehensive genome 
analysis in a standard clinical setting (Chung et al., 2015). Furthermore, Chung et al. (2015), 
analysed 236 cancer-related genes in 252 formalin-fixed paraffin-embedded (FFPE) HNSCC 
from a variety of locations including regional and distant metastasis. In concordance with the 
previously mentioned study, PIK3CA was the most frequently mutated gene in the 84 HPV-
positive tumours. Other frequently mutated genes in HPV-positive tumours included PTEN, 
SOX2 and MLL2. In the HPV-negative tumours again TP53 and CDKN2A were frequently 
mutated. In both HPV-positive and HPV-negative tumours mutations in tumour suppressor 
genes were more common than in oncogenes, although HPV-positive tumours had a higher 
likelihood of having only oncogene expression compared to HPV-negative tumours (Chung 
et al., 2015). Similar mutational profiles were also found in smaller studies, specifically 
examining genes commonly mutated in cancer (Lechner et al., 2013; Seiwert et al., 2015; 
Tinhofer et al., 2016), as well as by whole genome sequencing (Stransky et al., 2011).   
In addition to in OPSCC, HPV has also been implicated as a causative agent in a small 
proportion of hypopharyngeal squamous cell carcinoma cases (Dalianis et al., 2015; Wendt et 
al., 2014) and HPV is also sometimes found in other types of HNSCC, e.g. in approximately 
4-5% of oral- and laryngeal SCC (Plummer et al., 2016). However, the IARC does not 
consider HPV as a causative agent in these cancer types (IARC-Monographs, 2007).  
In the next section, OPSCC, where HPVs causal role is well established, is presented (IARC-
Monographs, 2007). 
1.3.2 Oropharyngeal squamous cell carcinoma (OPSCC) 
Anatomically, the oropharynx includes the tonsils, the base of tongue, the soft palate, the 
uvula and the back wall of the pharynx posterior to the oral cavity (Wenig, 2016). HPV 
causes cancer of the tonsils (TSCC) and the base of tongue (BOTSCC), the two subsites of 
the oropharynx containing lymphoid tissue, but is typically not involved in the carcinogenesis 
of the other oropharyngeal locales (Haeggblom et al., 2017; Marklund et al., 2012). 
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HPV-positive OPSCC, especially TSCC and BOTSCC, appear to be different clinical and 
biological diseases as compared to their corresponding HPV-negative counterparts, with 
HPV-positive tumours more often affecting younger people and non-smokers than HPV-
negative tumours (O´Sullivan et al., 2015). Notably, the metastases from HPV-positive TSCC 
and BOTSCC are frequently (30-50%) cystic, while the metastases from HPV-negative 
HNSCC most often are solid (O´Sullivan et al., 2015). See also above section on the genetic 
differences between HPV-positive and HPV-negative HNSCC. 
A sharp rise in the incidence of OPSCC, and especially TSCC and BOTSCC has been 
observed since 1970 in many countries including Sweden (Chaturvedi et al., 2011; Näsman et 
al., 2009; Rietbergen et al., 2013). Today, approximately 325 persons are diagnosed with 
OPSCC per year in Sweden, of which ~70% are men and ~75% of the tumours are HPV-
positive (Nationellt vårdprogram Huvud- och Halscancer 2015; Näsman et al., 2015). The 
proportion of HPV-positive OPSCC varies considerably between countries with a higher 
proportion in e.g. Sweden (Näsman et al., 2015) and the USA (Chaturvedi et al., 2011) as 
compared to e.g. in Germany (Tahtali et al., 2013) and the Netherlands (Rietbergen et al., 
2013). Furthermore, the proportions of HPV-positive TSCC and BOTSCC have increased the 
last decades (Chaturvedi et al., 2011; Näsman et al., 2009), analogous to the increase in 
TSCC and BOTSCC incidence, leading to the hypothesis that an HPV-epidemic is causing 
the rise in TSCC and BOTSCC incidence (Chaturvedi et al., 2011; Näsman et al., 2009).  
The incidence of HPV-negative TSCC and BOTSCC in contrast, are decreasing in some 
countries, e.g. in Sweden and the USA, likely due decreased smoking in these countries 
(Chaturvedi et al., 2011; Näsman et al., 2009). 
Notably, patients with HPV-positive TSCC or BOTSCC have significantly much better 
clinical outcome than patients with HPV-negative TSCC or BOTSCC (Ang et al., 2010; 
Chaturvedi et al., 2011; Lindquist et al., 2007), with approximately 80% versus 40% 5-year 
disease-free survival in Sweden, respectively, in the study by Lindquist et al. (2007). HPV-
status, however, does not clearly appear to have a prognostic effect at other oropharyngeal 
sites than the tonsils or base of tongue (Marklund et al., 2012). 
1.3.3 Cancer of unknown primary in the head and neck region (HNCUP) 
In 3-5% of all head and neck cancer cases, a primary tumour is not found despite a thorough 
clinical workup - so called cancer of unknown primary (HNCUP) (Pavlidis & 
Pentheroudakis, 2012). Between 2008 and 2012, in Sweden, there were 233 cases of 
HNCUP, and this calculates to an incidence rate of 0.49 cases per 100 000 inhabitants 
(Nationellt vårdprogram Huvud- och Halscancer, 2015). As other head and neck cancers, 
HNCUP is more common in men than in women. Squamous cell carcinoma is the most 
common form, accounting for 75-85% of the cases and will be the focus of the rest of the 
thesis (Cervezo et al., 2011; Nationellt vårdprogram Huvud- och Halscancer, 2015; 
O´Sullivan et al., 2015). 
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Previously it has been thought that CUP presenting at different parts of the body share 
common biological traits leading to rapid progression and early dissemination (Varadhachary 
& Raber, 2014). However, today increasing evidence points to CUP as different site-specific 
metastasis retaining the properties of the primary tumour, and that they just happen to share 
the attribute of having a primary tumour that escapes recognition (Pavlidis & Pentheroudakis, 
2012). Reasons for not finding the primary tumour includes that the primary tumour is very 
small and therefore missed during examination or due to spontaneous regression of the 
primary tumour (Cerezo et al., 2011). 
HNCUP has a much better clinical outcome than CUP in general with a 5-year survival of 35-
50% (Economopoulou et al., 2015), compared to CUP in general, which has a dismal 
prognosis with a median survival of only 6 to 10 months (Tothill et al., 2013). HNCUP thus 
appear to have more in common with head and neck cancer than with CUP at other parts of 
the body. 
It is likely that the more favourable clinical outcome in HNCUP could in part be due to that 
some of these tumours are in fact HPV-positive OPSCCs, or that they are regional metastases 
as opposed to distant metastases from a non-HNSCC tumour. In this thesis the first 
hypothesis has been examined in Paper I. 
Recently, a few studies have investigated genetic alterations in general CUP, however not 
taking into account specific subsites and including very few HNCUP. Ross et al. (2015), 
analysed 3769 exons from 236 cancer-related genes in 200 CUP and found at least 1 genetic 
alteration in 96% of the samples – most frequently TP53 (55%), KRAS (20%) and CDKN2A 
(19%) (Ross et al., 2015). They also subdivided the cohort into adenocarcinomas (ADC) 
(n=125) and non-ADC (n=75, including 8 SCC) with the same three genes as the most 
commonly mutated genes in both subgroups, although alterations in the receptor tyrosine 
kinase/RAS pathway were more often mutated in ADCs (Ross et al., 2015). Gatalica et al. 
(2014), analysed 1806 CUP with a variety of techniques including sequencing, 
immunohistochemistry (IHC) and in situ hybridization (ISH) in search of potential drug 
targets, finding mutations in 96% of the samples (Gatalica et al., 2014). TP53 and KRAS 
were the most frequently mutated genes with EGFR and HER2 the most commonly amplified 
genes (Gatalica et al., 2014). Tothill et al. (2013), examined 701 genes in 16 CUP patients 
including 3 HNSCC, two of them p16-positive by IHC, finding therapeutic gene targets or 
pathways in 12/16 (Tothill et al., 2013).  
Clearly, little is known about genetic changes in HNCUP, and in Paper II we therefore 
examined hotspot mutations in oncogenes and tumour suppressor genes in HPV-positive 
HNCUP. 
1.3.4 Benign conditions causing neck masses 
Cancer must always be excluded when a patient present with a neck mass. There are, 
however, a number of benign conditions causing neck masses and especially conditions 
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causing cystic lesions on the neck can pose a challenge to distinguish from a cystic metastasis 
from a HNSCC (Katabi & Lewis, 2017) 
In Table 2, a few benign conditions causing cystic lesions on the neck are mentioned and 
throughout the thesis branchial cleft cysts (BCC) will be discussed in more detail since this 
condition is well known to be particularly difficult to distinguish from cystic metastases 
(Gourin & Johnson, 2000). Notably, HPV-positive OPSCC neck metastases have been shown 
to frequently be cystic and thus pose a particular challenge to distinguish from BCCs, while 
HPV-negative OPSCC metastases rarely are cystic (O´Sullivan et al., 2015; Wenig, 2016). 
However, e.g. lymphomas, colloid nodular goiters and lymph nodes on the neck enlarged due 
to infection or sarcoidosis will not be discussed since they rarely are mistaken for a HNSCC. 
BCCs are congenital embryological remnants suggested to originate from the branchial 
apparatus in the neck (Wenig, 2016). They often present as a painless mass located on the 
lateral neck near the mandibular angle, often debuting between 20 and 40 years of age 
(Katabi & Lewis, 2017). They are quite common, representing 20% of all neck cysts and 
90% of cysts located on the lateral neck (Katabi & Lewis, 2017).  
The cysts are often lined with non-stratified squamous cell epithelium, but ciliated respiratory 
epithelium may also occur. The cyst walls contain lymphoid tissue giving them the 
alternative name lymphoepithelial cysts. The cysts can be associated with fistulas with 
openings in the pharyngeal wall or tonsillar region (Wenig, 2016). However, whether BCCs 
or other benign neck masses can harbour HPV has not been studied extensively and this will 
be discussed later in the thesis. 
Table 2. Examples of benign conditions that can cause cystic lesions on the neck (Katabi & 
Lewis, 2017). 
Branchial cleft cysts 
Thyroglossal duct cysts 
Ranula, also called renention cysts or mucocele 
Dermoid cysts 
Teratoid cysts 
Warthin’s tumours 
Pleomorphic adenomas 
Lymphangiomas 
 
1.4 DIAGNOSTIC PROCEDURES OF HEAD AND NECK MASSES 
1.4.1 Head and neck cancer including oropharyngeal squamous cell 
carcinoma 
In head and neck cancer the first sign of the disease, which brings the patient to the doctor, is 
often a lymph node metastasis on the neck presenting as a neck mass (Nationellt vårdprogram 
  13 
Huvud- och Halscancer, 2015). It can however also be due to symptoms such as pain, 
hoarseness, one-sided nasal congestion, difficulty swallowing or a mucosal wound that does 
not heal (O´Sullivan et al., 2015). The subsequent diagnostic workup includes e.g. fine-needle 
aspiration cytology (FNAC) of the neck mass, computed tomography (CT) of the head, neck 
& thorax, sometimes magnetic resonance imaging (MRI) of the head and neck, and tumour 
biopsies for a pathological anatomical diagnosis (PAD) if a primary tumour is evident. 
Together, these procedures reveal the site of the primary tumour in most cases and this is e.g. 
how OPSCC, including TSCC and BOTSCC are mainly diagnosed (Nationellt vårdprogram 
Huvud- och Halscancer, 2015). For OPSCC, HPV-analysis is often performed on FFPE 
biopsies, either using PCR for HPV DNA or analysing expression of the surrogate marker 
p16 using immunohistochemistry (O´Sullivan et al., 2015). Today however, some centres 
require the presence of both for defining positive HPV status (Näsman et al., 2013; Smeets et 
al., 2007). 
1.4.2 Cancer of unknown primary in the head and neck region 
In Sweden, the clinical investigation of HNCUP starts with the above-mentioned FNAC, CT 
and MRI. If no primary tumour is found the investigation continues. If the FNAC shows non-
SCC, e.g. adenocarcinoma, a PET-CT is recommended, since the primary tumour is then 
likely not a head and neck cancer, and today a full-body PET-scan is sometimes performed. 
Furthermore, a panendoscopy of the upper aerodigestive tract, including blind biopsies from 
the nasopharynx and base of tongue is performed, as well as bilateral tonsillectomy 
(Nationellt vårdprogram Huvud- och Halscancer, 2015). Location of a SCC metastasis in 
level I or II of the neck gives rise to suspicion of OPSCC, while a metastasis located in the 
lower part of the neck more likely has a non-head and neck cancer as a primary (Nationellt 
vårdprogram Huvud- och Halscancer, 2015). Since HNCUP is a diagnosis made after all 
other diagnoses have been excluded, the HNCUP diagnosis is dependent of the clinical work-
up that has been performed. The clinical investigation, e.g. if bilateral tonsillectomy (where 
TSCC may be detected) is performed, may vary between different centres, as well as different 
studies, and this influences the incidence of HNCUP, the proportion HPV-positive HNCUP 
as well as the clinical outcome in the studies (Boscolo-Rizzo et al., 2015). 
1.4.3 Branchial cleft cysts 
The clinical investigation of a suspected branchial cleft cyst is dependent on the age of the 
patient as the risk for head and neck cancer, which needs to be ruled out, increases with age. 
At the Karolinska University Hospital all patients receive a thorough clinical examination 
including palpation and fine-needle aspiration cytology (FNAC) on two occasions. For 
patients over 29 years of age the FNAC-analysis includes DNA-analysis, where aneuploidy 
indicates malignancy. If a tumour is suspected or apparent, panendoscopy including palpation 
and biopsies are performed. For patients over 40 years of age, a CT with intravenous contrast 
of the neck, thorax and base of skull is done, and in addition, if no tumour is evident during 
panendoscopy, bilateral tonsillectomy is performed and multiple biopsies are taken from the 
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base of tongue and epipharynx (Vårdprogram, Halscysta – Lateral., 2016). HPV-testing is 
infrequently performed on FNAC or surgical specimens (see Paper IV). 
1.4.4 HPV-detection in fine-needle aspirates from neck masses 
As mentioned above, fine-needle aspiration cytology (FNAC) of neck masses is an important 
step in the diagnostic work-up of a suspected HNSCC. The aspirate is smeared on a glass and 
examined using a light microscope. The sensitivity and specificity of this method depends on 
the quality of the aspirate and the smear and are improved if the procedure is guided by ultra 
sound (Nationellt vårdprogram Huvud- och Halscancer, 2015). Most often the method can 
distinguish between benign and malignant conditions, and between carcinomas, lymphomas 
and sarcomas, although the interpretation can be difficult at times and require specially 
trained personnel. The material obtained can also be used for molecular methods (Nationellt 
vårdprogram Huvud- och Halscancer, 2015). There are also liquid cytology methods 
available and detection of HPV using these methods can be employed in cervical cancer 
screening (Whitlock et al., 2011). However, FNAC is not used for the collection of material, 
since the uterine cervix is accessible for brushing and scraping. 
Being able to reliably detect HPV in FNAC from neck masses would be desirable and has not 
been studied extensively (Faquin, 2014). This would facilitate improved diagnosis and 
prognosis making in a number of malignant and benign conditions in the head and neck 
region and may lessen the need for more invasive procedures (Faquin, 2014). This would be 
especially true for HNCUP since a neck dissection sometimes is performed to validate the 
result from cytology with histopathology. Also, as mentioned above, if the metastasis is 
HPV-positive, then the primary tumour is probably an HPV-positive TSCC or BOTSCC 
(Begum et al., 2007) and the patients likely have a good prognosis (Ang et al., 2010; 
Lindquist et al., 2007). It is possible that these patients may not need as intensive treatment as 
patients with HPV-negative HNCUP, in analogy to the de-escalation of treatment that has 
been proposed for HPV-positive TSCC/BOTSCC (Mirghani et al., 2015). If HPV-diagnosis 
in FNAC is shown to be reliable enough, these patients could potentially be spared some 
treatment and subsequent adverse effects.  
There have been several studies investigating HPV-detection in FNAC from neck masses and 
they will be briefly mentioned below, for a more detailed review see Sivars et al. (2016). 
Unfortunately, most of the studies have been rather small and of retrospective character, 
using a variety of techniques (often ISH in the older studies), and a variety of starting 
material (smears or cell blocks, fresh frozen or FFPE) (Baldassarri et al., 2015; Barwad et al., 
2012; Begum et al., 2007; Bishop et al., 2012; Guo et al., 2014; Jannapureddy et al., 2010; 
Kerr et al., 2014; Lastra et al., 2013; Smith et al., 2014; Solomides et al., 2012; Umudum et 
al., 2005; Zhang et al., 2008). Typically, the studies find that HPV-detection is feasible, but 
not perfect and that a finding of HPV can predict an OPSCC with a very good specificity of 
90-100%, but only with an average sensitivity of 50-60% (Begum et al., 2007; Jannapureddy 
et al., 2010; Zhang et al., 2008;). There are also a few studies using commercially available 
methods for HPV-detection in gynaecological cytology samples, showing promise for the 
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analysis of FNAC samples as well, although these methods were not perfect either (Bishop et 
al., 2012; Guo et al., 2014; Lastra et al., 2013; Smith et al., 2014). Recently, in addition, two 
prospective studies have been performed using the Roche cobas 4800 system (Roche 
Molecular System, Pleasanton, CA) for HPV detection, showing >90% correlation of HPV-
status between cytology and FFPE material (Baldassarri et al., 2015; Kerr et al., 2014), as 
well as being highly indicative of an OPSCC (Baldassarri et al., 2015). 
To summarize, HPV detection in FNAC shows great promise, but there is at the moment no 
consensus of which method that is the best, neither concerning how to best prepare and store 
the sample until testing, nor how to best detect DNA (Faquin, 2014). Furthermore, in the 
above studies mostly patients with malignancies where examined. It would be interesting to 
test for HPV DNA in FNAC, as well as HPV mRNA, in a broader unselected cohort of 
patients with unknown neck masses. In this thesis we have attempted to do just this in Paper 
IV. 
1.5 TREATMENT OF HEAD AND NECK MASSES 
1.5.1 Head and neck cancer 
Treatment of HNSCC varies depending on subsite, but can consist of surgery, radiotherapy or 
chemotherapy, alone or in combinations (O´Sullivan et al., 2015). In addition, the EGFR-
inhibitor cetuximab is approved for use in HNSCC (O´Sullivan et al., 2015) and, very 
recently, immune checkpoint inhibitors have been approved in recurrent HNSCC (Ferris et 
al., 2017). Below, the treatment for OPSCC will described briefly, and the treatment for 
HNCUP will be described in greater detail. 
1.5.2 Oropharyngeal squamous cell carcinomas 
Radiotherapy (RT) in a curative dose is the main treatment option in Sweden today. 
Chemotherapy (cisplatin) or targeted therapy (cetuximab) is often added in advanced cases. 
Surgery can be applied in selected cases, or if there is tumour left on the neck after RT 
(Nationellt vårdprogram Huvud- och Halscancer, 2015). However, since HPV-positive TSCC 
and BOTSCC have much better clinical outcome than corresponding HPV-negative cancer, it 
has been suggested that treatment could be de-escalated for HPV-positive cancer (Mirghani et 
al., 2015). For this purpose, several studies have focused on finding additional predictive 
markers to use in conjunction with HPV, and in some studies, it has been shown e.g. that high 
CD8+ lymphocyte counts, and low or absent HLA class I expression was correlated to better 
prognosis in HPV-positive cancer (Nordfors et al., 2014; Näsman et al., 2013;). 
1.5.3 Cancer of unknown primary in the head and neck region 
Treatment of HNCUP varies between different centres and there is a lack of evidence for 
what treatment is optimal (Balaker et al., 2012). The main treatment options today consist of 
either neck dissection with post-operative radiotherapy or radiotherapy with or without 
chemo-/targeted therapy (Nationellt vårdprogram Huvud- och Halscancer, 2015). Neck 
dissection allows confirmation of the cytological diagnosis with histopathology. In a radical 
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neck dissection, all lymph nodes in levels I to V are removed as well as the 
sternocleidomastoid muscle, the internal jugular vein and the accessory nerve. Today, a 
modified radical neck dissection is often performed instead, which spares as many structures 
as possible depending on the anatomy of the individual patient. The radiotherapy consists of 
up to 68 Gy, in advanced cases with concomitant chemotherapy, most often cisplatin based. 
However, sometimes the EGFR-inhibitor cetuximab is used as an adjuvant instead. The 
radiotherapy often leads to severe side effects, e.g. mucositis with subsequent pain, difficulty 
swallowing and nutritional difficulties, as well as skin reactions, dry mouth and 
osteoradionecrosis. Surgery could lead to adverse effects such as pain, lymph oedema, nerve 
damage as well as cosmetic issues (Nationellt vårdprogram Huvud- och Halscancer, 2015). 
If in fact an HPV-positive HNCUP originates from an HPV-positive OPSCC, then treatment 
could potentially be tapered for this group of tumours. Therefore, in Papers I and II, in 
addition to HPV status, CD8+ tumour infiltrating lymphocytes (TILs), HLA class I 
expression and p53 status were investigated in HNCUP in correlation to clinical outcome in 
order to find additional biomarkers. 
1.5.4 Branchial cleft cysts 
If nothing malignant is found during investigation (see above) and a branchial cleft cyst is the 
final diagnosis and the patient is below 40 years of age, the cyst is carefully extirpated 
avoiding it’s braking. If the patient is 40 years old or above, a more extensive procedure is 
performed, where lymph nodes in the same neck region as the cyst are removed in addition to 
the cyst (Vårdprogram, Halscysta – Lateral, 2016). Patients with branchial cleft cysts thus 
clearly undergo extensive invasive procedures as part of the diagnostic procedure and 
treatment, with subsequent side effects, including risk for damage to the hypoglossal-, 
superior laryngeal-, vagal-, glossopharyngeal- and accessory nerves as well as to the jugular 
vein and carotid artery, if surgery is applied, despite having a benign condition 
(Vårdprogram, Halscysta – Lateral, 2016). 
 
1.6 REFLECTIONS ON PERSONALIZED TREATMENT IN HNCUP, OPSCC 
AND BRANCHIAL CLEFT CYSTS 
Cancer is not one disease, but many, and this applies also to HNC, including OPSCC and 
HNCUP. Therefore, all patients with a certain condition should not necessarily be treated the 
same way. For branchial cleft cysts, the scope of the diagnostic procedures and the optimal 
treatment for different age groups is still a matter of debate. 
Notably, patients with OPSCC receive the same treatment, regardless of that patients with 
HPV-positive TSCC and BOTSCC have, as mentioned previously, a significantly better 5-
year survival than patients with HPV-negative TSCC or BOTSCC. Despite this, they are 
treated similarly and the treatment for all TSCC and BOTSCC has furthermore been 
intensified in recent years. It is plausible that all patients with HPV-positive TSCC/BOTSCC 
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are not helped by this intensified approach and de-escalation of treatment for this patient 
group has therefore been suggested (Mirghani et al., 2015). There are currently several de-
escalation trials ongoing (Mirghani et al., 2015). On the other hand, for TSCC/BOTSCC-
patients with a poor prognosis there is need for new treatments as well as biomarkers to 
identify these patients. 
For HNCUP there is, as already mentioned, a controversy as to if a neck dissection should be 
performed or not (Balaker et al., 2012) and biomarkers selecting patients that could benefit 
from having (or not having) the extensive surgical procedure would be welcome. If an HPV-
positive HNCUP has a much better prognosis than an HPV-negative HNCUP, diagnosing 
HPV-positive status of the HNCUP could potentially be used to select a less intensive 
treatment, in analogy to the de-escalation of treatment proposed for HPV-positive 
TSCC/BOTSCC. However, one complicating matter for HNCUP is that it is such a rare 
entity making randomized controlled trials between different treatments difficult to perform.  
In addition, biomarkers that could help find the likely site of the primary tumour could help 
steer further diagnostic procedures and treatment (e.g. RT) towards the suspected location, 
potentially sparing other locations. If HPV-positive HNCUP indeed originates from HPV-
positive TSCC/BOTSCC, as has been suggested, HPV-positive status of an HNCUP could 
potentially steer investigation and therapy towards the oropharynx. 
For patients with branchial cleft cysts there are other challenges. These patients undergo 
extensive invasive procedures as part of diagnostics and treatment in order to rule out an 
HNC. The major challenge here is that it is sometimes difficult to distinguish BCCs from 
cystic metastases. Today, if HPV is found in a cervical cyst it is assumed to be a metastasis 
from an HPV-positive TSCC/BOTSCC. However, whether HPV is found or not in other 
cervical cysts, e.g. BCCs, have not been studied extensively. If it can be ruled out that BCCs 
harbour HPV DNA, investigation of HPV-status would be of value in the clinical work-up of 
BCCs, potentially helping to discriminate between BCCs and cystic TSCC/BOTSCC 
metastases. Further studies would then be needed to evaluate if HPV-negative status (together 
with a clear benign cytology) in a BCC could potentially influence treatment. 
To summarize, some treatments work well for some patients, but not as well for others. 
Personalized treatment would therefore be very welcome to avoid overtreatment leading to 
unnecessary side effects for some patients and under treatment of others. Still, to facilitate the 
realisation of personalised treatment in HNSCC, more knowledge is needed. In the next 
section, questions unanswered at the time of the initiation of this thesis project are presented. 
Since then, we have tried to answer some of these questions and these are presented in the 
papers of this thesis. 
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1.7 UNANSWERED QUESTIONS AT THE TIME WHEN THIS THESIS PROJECT 
WAS INITIATED 
In 2013, when I as a medical student started working on the projects described in this thesis, 
the role of HPV in HNCUP had not been studied extensively. Although, HPV DNA had been 
found in HNCUP in a few studies (Compton et al., 2011; Park et al., 2012; Tribius et al., 
2012), the prognostic implications of positive HPV-status were inconclusive: two studies had 
failed to show any prognostic effect of positive HPV-status (Compton et al., 2011; Tribius et 
al., 2012), while one did show a survival benefit (Park et al., 2012). The study by Park et al. 
(2012), however, included patients who had not undergone bilateral tonsillectomy, a 
procedure nowadays part of the standard clinical work-up of HNCUP, and which often leads 
to that a primary tumour is found – frequently an HPV-positive TSCC with a good prognosis. 
These patients would therefore not be classified as HNCUP today. Furthermore, the presence 
of HPV mRNA and the prognostic significance of additional biomarkers had not been studied 
extensively in HNCUP. For this purpose, we investigated these issues in Papers I and II. 
Moreover, as mentioned above, the mutational landscape of HPV-positive HNCUP was 
largely unexplored and the prognostic significance of different mutations in OPSCC not fully 
elucidated. We analysed these two topics in Paper III. 
Additionally, if presence of HPV DNA in FNAC from a cervical lymph node could 
accurately predict an HPV-positive TSCC or BOTSCC as final diagnosis in a broad and 
unselected cohort of patients with benign and malignant neck masses had not been studied 
prospectively. Such a study was therefore conducted and described in Paper IV. 
Finally, if HPV DNA is present in other neck masses than metastases from HPV-positive 
TSCC/BOTSCC, e.g. in branchial cleft cysts, had not been investigated thoroughly, 
something we also examined in Paper IV. 
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2 AIMS 
 
• To examine the prevalence of HPV DNA in HNCUP, and whether HPV DNA and/or 
p16-status, as well as p53-expression were correlated to clinical outcome. (Paper I) 
 
• To validate our findings regarding HPV DNA, p16 and p53 from Paper I in a separate 
HNCUP cohort and also to analyse additional biomarkers: HPV16 mRNA, CD8+ 
tumour infiltrating lymphocytes (TILs), and HLA class I expression in relation to 
clinical outcome in the combined cohorts. (Paper II) 
 
• To find prognostic markers in TSCC/BOTSCC, as well as to compare the presence of 
hot spot mutations in cancer related genes in HPV-positive TSCC/BOTSCC, HPV-
negative TSCC/BOTSCC and HPV-positive HNCUP using targeted next generation 
sequencing. (Paper III) 
 
• To investigate whether the detection of HPV DNA and HPV16 mRNA in FNAC was 
reliable, whether HPV detection in FNAC from a neck mass could prospectively 
predict an HPV-positive TSCC/BOTSCC as the final diagnosis or whether HPV 
DNA was present in benign neck masses, e.g. branchial cleft cysts, as well. (Paper 
IV) 
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3 STUDY SUBJECTS, MATERIAL AND METHODS 
 
3.1 GENERAL INTRODUCTION TO METHODS OF HPV-DETECTION IN 
HNSCC 
Detection of HPV in patient material can be done in numerous ways including detection of 
HPV DNA or RNA, viral proteins in the material, or detection of proteins that are 
upregulated by HPV. Detection of antibodies against HPV in serum can also be investigated. 
Which method that is the best is under debate and varies according to what material you have 
access to and whether you are interested on HPV infection on the individual or the population 
level (Näsman A, 2013; Venuti & Paolini, 2012). 
Presently, detection of E6 and E7 mRNA in fresh-frozen tumour tissue is generally regarded 
as the golden standard (Smeets et al., 2007, Venuti & Paolini, 2012). Fresh-frozen tissue is 
however often not easily available, since it is impractical in routine clinical practise and 
therefore formalin-fixed paraffin-embedded (FFPE) material is often used instead. When 
working with FFPE material, HPV DNA can be analysed by several techniques including 
fluorescent in situ hybridization (FISH), a variety of different PCR-based techniques, or by 
sequencing, with the first two being the most common (Venuti & Paolini, 2012). However, 
just finding HPV DNA in the tumour does not automatically prove that the neoplasm is HPV-
driven – it could be due to a transient infection or a false positive due to the high sensitivity of 
e.g. PCR (Smeets et al., 2007).  
Overexpression of the p16-protein is often used a surrogate marker of HPV-driven 
carcinogenesis, since p16 is usually upregulated upon loss of pRb during HPV infection 
(Venuti & Paolini, 2012). Furthermore, p16 is often lost in other forms of cancer, including 
HPV-negative HNSCC, making p16 overexpression useful as a surrogate marker for HPV 
(Cancer Genome Atlas Network, 2015; Venuti & Paolini, 2012) Nevertheless, upregulation 
of p16 can still occur and around 14% of HPV DNA-negative OPSCC is also p16-positive 
(Lewis et al., 2010). It has therefore been proposed that initial immunohistochemistry (IHC) 
staining for p16 followed by HPV DNA analysis of the p16 positive tumours would be the 
best way of determining clinically relevant HPV infections (Smeets et al., 2007). Notably, 
combining p16 overexpression with presence of HPV DNA, showed an impressive 100% 
sensitivity and specificity when applying this algorithm compared to HPV E6 expression 
(Smeets et al., 2007) and the algorithm was later validated showing an accuracy of 98% 
(Rietbergen et al., 2013). However, HNSCC expressing HPV DNA and E6*1 mRNA, but 
lacking p16 overexpression, have also been described and would have been missed using this 
approach (Hoffman et al., 2012).  
In the clinic, and in research studies, HPV DNA (by PCR or ISH) or p16 (by IHC) status are 
sometimes used alone when determining HPV-status, something that is not optimal, 
considering that there also are HPV-/p16+ and HPV+/p16- cases. Applying a conservative 
definition of HPV-positivity, i.e. requiring positivity for both HPV DNA and p16, is 
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especially important when selecting patients for de-escalating trials in order not to lessen the 
treatment for patients with poor prognosis. This routine could miss some patients according 
to Hoffman et al (2012), but it is still a safer approach than using HPV DNA or p16 
expression alone. The definition of p16 overexpression, i.e. p16-positive, has varied, but for 
an indication of active HPV infection today a cut-off of >70% of the tumour cells presenting 
intense staining is mainly used (Ang et al., 2010; Lassen et al., 2012). It is worth noting that 
this cut-off has been set rather arbitrarily, but that this rarely poses a problem in OPSCC 
(according to the experience of others and us), since p16 almost always presents with either 
100% or 0% of tumours cells being stained, making interpretations straight-forward (Lassen 
et al., 2012). 
In this thesis, FFPE material was used for HPV DNA detection and p16 analysis in Papers I, 
II and III as well as HPV mRNA detection in Paper II and next generation sequencing (NGS) 
in Paper III, while fresh-frozen FNACs was used for HPV DNA and RNA detection in Paper 
IV. See below for further details. 
 
3.2 STUDY SUBJECTS AND PATIENT MATERIAL 
Below, study subjects and patient material will be briefly presented for each paper and then 
some considerations worth noting will be touched upon. For more details please see 
respective paper. 
    Paper I. Patients with HNCUP as defined by ICD-10-code C.77.0 diagnosed between 
2000 and 2007 at the Karolinska University Hospital, Stockholm, Sweden with available 
FFPE-material for analysis were identified from hospital records and included in the study. 
Patients only given palliative treatment, or with histology other than SCC, or patients 
declining post-operative radiotherapy or lacking sufficient FFPE-material were excluded, 
leaving 50 patients in the study. Patients’ data were obtained from medical records. 
    Paper II. All patients with HNCUP (with the same definition as in paper I, above) 
diagnosed at the Karolinska University Hospital, Stockholm, Sweden between 2008 and 
April 30th 2013 were identified through the Swedish Cancer Registry. Using the same 
inclusion- and exclusion criteria as mentioned for Paper I, this resulted in another 19 patients 
included in Paper II. These 19 patients were used for the validation of the effect of HPV 
DNA and p16 expression on survival, while the combined 2000-2013 cohorts of 69 patients 
were used for HPV mRNA analysis and the additional biomarker analysis performed. 
    Paper III. In a study on hotspot mutations of 50 cancer-related genes, all 20 HPV DNA-
positive HNCUP samples from Paper I were included together with a total of 348 TSCC 
(ICD-10-code C09.0-9) and BOTSCC (ICD-10-code C01.9) diagnosed 2000-2011 at the 
Karolinska University Hospital. HPV DNA-, p16- and patient data for the included 
TSCC/BOTSCC were derived from previous studies, where FFPE-material had been used 
(Nordfors et al., 2014; Näsman et al., 2013; Ramqvist et al., 2015). 
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    Paper IV. Patients undergoing FNAC for a suspected HNSCC/neck mass of unknown 
origin at the Karolinska University Hospital between 2013 and 2016 were prospectively 
included in the study. Sixty-six patients had enough material left after routine cytological 
diagnostic procedures had been performed. The left-over aspirates were fresh-frozen at -20℃ 
and analysed as soon as possible. 
Study subjects and patient material considerations: As noted previously, HNCUP is a 
difficult diagnosis to define. One example of this is that in four patients, included in Papers I 
and II, a suspected primary tumour was found during follow-up, years after the diagnosis was 
set. Would these classify as a true HNCUP? Some would argue not (Jensen et al., 2014). We 
however decided to include these patients in the studies, since we were interested in patients 
defined as having HNCUP at the time of diagnosis, when the physicians decide on the 
treatment. After all, physicians cannot, unfortunately, see into the future. The diagnoses of 
these four indicated patients have been commented on in the discussion parts of the papers. 
In Paper IV HPV analysis on FNACs was performed. Over the course of two and half year a 
total of 66 samples were collected. Samples were collected prospectively when suitable for 
the collecting clinician and when enough material remained after routine clinical procedures. 
Therefore, obviously not all the patients that had a neck mass of unknown origin analysed by 
FNAC at the Karolinska University Hospital during the time period could be included, and a 
selection bias could have been introduced into the study. 
 
3.3 METHODS 
3.3.1 HPV DNA and RNA extraction 
In Paper I DNA, and in Paper II DNA and RNA were extracted from FFPE cervical lymph 
nodes resected during neck dissection using the Roche High Pure RNA Paraffin Kit (Roche 
Diagnostics, Mannheim, Germany) according to manufacturer’s instructions, but omitting the 
DNAse treatment. In Paper III DNA had been extracted previously from FFPE biopsies from 
TSCC and BOTSCC using the same method. In Paper IV DNA was extracted from fresh-
frozen aspirates from neck masses using the QIAmp DNA micro kit (Qiagen, Hilden, 
Germany) and if the aspirate was HPV DNA-positive, RNA was extracted using the RNeasy 
Micro kit (Qiagen, Hilden, Germany). 
Methodological considerations: The Roche High Pure RNA Paraffin Kit is optimized for 
RNA retrieval; however, it also works fine for extracting DNA and has been in use in our 
group for a long time (Nordfors et al., 2014; Näsman et al., 2013). As mentioned above, DNA 
quality in FFPE material is inferior to the DNA quality of fresh-frozen material but is more 
easily available. Nevertheless, HPV DNA detection from FFPE material is standard 
procedure at pathology laboratories. In Paper IV we had access to fresh-frozen aspirates. 
However, due to practical reasons at the clinic the samples were frozen and stored at -20oC 
and not -70oC. This may have affected our ability to detect HPV RNA. To check for cross 
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contamination between samples, in all studies, blanks were added and treated in same way as 
the samples. 
3.3.2 HPV DNA and RNA detection 
The method for HPV DNA-detection used in this thesis has been developed in Heidelberg, 
Germany by the Michael Pawlita group and consists of two parts, which will be briefly 
described below: first a multiplex PCR and then a Luminex bead-based assay for 27 HPV 
types (Schmitt et al., 2006; Schmitt et al., 2008). A similar method is applied for HPV RNA 
detection (Ramqvist et al., 2015). 
For the HPV DNA PCR, the broad-spectrum general primers (BSGP) 5+/6+ primers that bind 
to the well-conserved L1 region of the HPV-genome were used. In addition, specific primers 
directed against HPV16 E6 and HPV33 E6, were added to detect the rare cases, where L1 
had been deleted in tumours associated with these HPV-types. As an HPV-positive control, 
samples with DNA from SiHa cells, corresponding to around 1,10 and 100 genomes of 
HPV16 per 5µl respectively, were used, while specific primers of the housekeeping gene β-
globin were used to control for presence of amplifiable cellular DNA. Finally, RNAse free 
water was used as negative control. 10 ng of extracted DNA was added for each reaction. See 
Schmitt et al., (2008), for the primers used. A 15 minutes denaturation step at 94°C was 
followed by 40 cycles of amplification. Each cycle consisted of a 20 second denaturation step 
at 94°C followed by a 90 second annealing step at 38°C and an 80 second elongation step at 
71°C. The final elongation step was prolonged for 4 minutes (Nordfors et al., 2014). 
For RNA detection in Papers II and IV, the samples were DNAse treated using the RNeasy 
MiniElute Cleanup kit (Qiagen, Hilden, Germany) if needed, and then cDNA was 
synthesized using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) with random hexamer primers used. A PCR was then run to amplify 
HPV16 E2, E5, E6*1, E6*2 and E7 mRNA. The housekeeping gene U1A was used to check 
for presence of amplifiable RNA and absence of β-globin was used to control that no DNA 
was still present in the sample. See Ramqvist et al. (2015) and Papers II and IV for more 
details and the specific primers used (Ramqvist et al., 2015). 
The amplified DNA and RNA was then analysed using a bead-based assay on a Magpix 
instrument (Luminex Corp). The HPV DNA assay included 27 HPV types: HPV6, 11, 16, 18, 
26, 30, 31, 33, 35, 39, 42-45, 51-53, 56, 58, 59, 66-70, 73 and 82, thus including all HR and 
putative HR HPV types and a number of LR types. The assay also included HPV16 and 
HPV33 E6 and β-globin.  The RNA assay was more limited and included HPV16 E2, E5, 
E6*1, E6*2 and E7 mRNA, U1A and β-globin (Ramqvist et al., 2015).  
The Magpix assay allows for simultaneous detection of up 50 different molecules in a single 
sample. Briefly, magnetic beads with different colours are coupled to probes specific for the 
molecules to be measured. Here, e.g. DNA of 27 different HPV-types was coupled to beads 
with 27 different colours. The previously generated PCR-products were denatured and 
hybridized to the bead-probe complex. Unhybridized DNA was then washed away and the 
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PCR-products stained with a flourescent reporter dye. After another washing step, the beads 
were analysed by two lasers in the Luminex reader. More specifically, one laser evaluates the 
colour of the beads determining which HPV-types are present, while the other laser detects 
the reporter dye and semi-quantifies the amount of HPV DNA (or mRNA). The result is 
given as median fluorescence intensity (MFI) (Schmitt et al., 2006).  
In this thesis, to exclude false positive signals and cases where the HPV DNA concentration 
was clearly too low to be causative of HNSCC, samples were considered positive if the MFI 
– (1.5xbackground +15) was above 100. 
Methodological considerations: The BSGP 5+/6+ primers are a development from the GP 
5+/6+ primers (Schmitt et al., 2008). The original GP5+/6+ primers have good sensitivity for 
e.g. HPV16 (approximately 10 copies needed), but considerably weaker sensitivity for other 
HPV types, e.g. 10 000 – 10 0000 genome copies would be needed for detection of certain 
HPV-types (Schmitt et al., 2006). By using the developed broad-spectrum GP 5+/6+ primers 
the sensitivity is more equal among the HPV types included in the assay, although still 
somewhat variable (Schmitt et al., 2008). Nevertheless, since HPV16, for which the 
sensitivity is extremely good, is the clearly dominating type in HNSCC, this did likely not 
pose a problem for the studies included in this thesis. Furthermore, the BSGP 5+/6+ primers 
are also a good choice when working with FFPE material, which often contain fragmented 
DNA, since they result in a shorter product (around 150 bp) than e.g. the PGMY9/PGMY11 
primers, which give a product of around 450bp (Venuti & Paolini, 2012). Finally, the Magpix 
assay allows for simultaneous detection of many HPV-types (or mRNAs) in a single sample, 
making it a time saving and rather affordable method when working with large sets of 
samples (Schmitt et al., 2006). 
3.3.3 Immunohistochemistry (IHC) 
The standard IHC procedure applied in this thesis consisted of 4µm FFPE sections initially 
de-paraffinized and re-hydrated followed by antigen-retrieval in citrate buffer in a microwave 
oven. Thereafter were endogenous peroxidase activity quenched using hydrogen peroxide 
and slides were treated with horse serum to block unspecific binding sites. Thereafter, the 
slides were ready to be incubated with the primary antibody (see below). After incubation 
with the first antibody, a biotinylated secondary anti-mouse antibody was applied (dilution 
1:200, Vector Laboratories, Burlingame, USA) followed by incubation with an avidin-biotin-
complex (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, USA). The slides were 
then developed in DAB (Vector Laboratories, Burlingame, USA) and counterstained using 
haematoxylin. All evaluations were performed using light microscopy with researchers 
blinded to clinical outcome. 
p16 
In Paper I the primary antibody p16INK4a (clone: JC8, dilution 1:100, Santa Cruz Biotech, 
Dallas, USA) was applied overnight at 8℃ to study p16 expression. This antibody had 
previously been used for the p16 data included in Paper III. However, when the study in 
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Paper II was initiated this antibody was no longer available, and instead the antibody from the 
Ventana Cintec p16 Histology kit (Roche AB, Stockholm, Sweden) was incubated with the 
sample undiluted (as it was ready to use) for 30 minutes at room temperature. In Paper IV, 
p16 data was collected from patient records if available. Slides were considered p16-positive 
if >70% of tumour cells exhibited strong staining in all papers (Ang et al., 2010; Lassen et al., 
2012). 
p53 
In Papers I and II the mAb p53 (clone: DO-1, dilution 1:100, Santa Cruz Biotech, Dallas, 
USA) that recognises both wild-type and mutant p53 was applied overnight at 8℃ to study 
p53 expression. The percentage of tumour cells stained was then estimated (Yemelyanova et 
al., 2011). 
CD8+ tumour infiltrating lymphocytes (TILs) 
In Paper II the mAb CD8 (clone: 4B11, dilution 1:40, Leica Biosystems, Newcastle, UK) was 
used overnight at 8℃ to study the number of CD8+ TILs. Two researchers independently 
counted the number of stained lymphocytes in five randomly selected representative 40x high 
power magnification fields of tumour tissue. The average number of the 10 observations was 
then used to divide the patients into quartiles (Nordfors et al., 2014). 
HLA Class I expression 
To study HLA Class I expression in the tumours in Paper II the mAb HC10/HLA Class I 
(dilution 1:40, a kind gift from Dr Soldano Ferrone at the University of Pittsburgh, PA, USA) 
was applied overnight at 8℃. The tumour tissue in the samples was then scored to have 
absent staining, weak staining intensity (compared to surrounding normal tissue) or high 
staining intensity (the same intensity as surrounding normal tissue) (Näsman et al., 2013). 
Methodological considerations. The difficulty with IHC does not lie so much in the method 
itself, but in the interpretation of the staining achieved. Inter- and intra-observer variability 
can be considerable.  
For p16 however, this is rarely a problem since, as mentioned above, typically all or none of 
the tumour cells show strong staining (Lassen et al., 2012). Furthermore, notably between 
Paper I and Paper II, the antibody used to analyse p16 expression differed, since the first 
antibody no longer was commercially available. This however did not likely affect the data in 
a major way, since only modest differences were observed between the two antibodies for 
p16 detection in a recent study (Shelton et al., 2017). 
The counting of CD8+ TILs is tedious, but in general straightforward. However, a few 
tumours show marked intra-tumour heterogeneity regarding the number of CD8+ TILs in 
different areas of the tumour and can be more difficult to evaluate.  
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P53 staining and HLA Class I expression are somewhat more difficult to interpret, especially 
given intra-tumour heterogeneity. To minimize errors, all IHC analysis were performed 
independently by two researchers who had to agree to a unanimous decision, otherwise the 
sample was analysed again. 
It is also worth noting that p53 analysis by IHC is tricky, since the functioning antibodies 
used cannot distinguish between mutant and wild-type p53. An overexpression could thus 
consist of either mutant, non-functional p53 (which would presumably be bad for the 
outcome) or of functional p53 (which would presumably be good), perhaps creating a mixed 
population among the group showing high p53 expression. Moreover, tumours with p53 
mutations have in some cases been shown to display a complete absence of p53 staining upon 
IHC examination, further complicating p53 analysis by IHC (Yemelyanova., 2011). 
3.3.4 Sequencing 
In Paper III, targeted next generation sequencing was performed on OPSCC and HPV-
positive HNCUP. The method is better described elsewhere, e.g. in Paper III and will only be 
summarily described here. Briefly, the Ion AmpliSeq Cancer Hotspot Panel v2 (Thermo 
Fisher Scientific, Waltham, USA) was used to amplify by PCR mutation hotspots in 50 genes 
commonly mutated in cancer, covering around 2800 hotspots described in the Cosmic 
database. See Table 3 for the genes included. Sequencing was performed on an Ion Proton 
benchtop sequencing platform (Thermo Fisher Scientific, Waltham, USA) and the Torrent 
Suite Software (Thermo Fisher Scientific, Waltham, USA) was used for variant calling. 
Samples with poor DNA quality, germline mutations, and variants with projected low impact 
were excluded, see Paper III for details. 
Methodological considerations: Performing NGS on FFPE material is not ideal since 
formalin fixing may lead to fragmentation of DNA and thus poor DNA quality. For HPV 
DNA detection this does not pose a problem, but for sequencing it can, especially when 
performing whole genome sequencing with large amplicons. Furthermore, deamination 
artefacts leading to false positives can occur with FFPE-material (Moorcraft et al., 2015). In 
Paper III, however targeted sequencing was performed, which works better with fragmented 
DNA, since the amplicons are shorter. Internal controls were also used to check the DNA 
quality. Furthermore, the method used has previously been documented to work well with 
FFPE material (de Leng et al., 2016). Nonetheless, a few mutations that might have been 
detected if using fresh-frozen material could have been missed. 
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Table 3. Genes included in the Ion AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher 
Scientific, Waltham, USA). 
ABL1 EGFR GNAS KRAS PTPN11 
AKT1 ERBB2 GNAQ MET RB1 
ALK ERBB4 HNF1A MLH1 RET 
APC EZH2 HRAS MPL SMAD4 
ATM FBXW7 IDH1 NOTCH1 SMARCB1 
BRAF FGFR1 JAK2 NPM1 SMO 
CDH1 FGFR2 JAK3 NRAS SRC 
CDKN2A FGFR3 IDH2 PDGFRA STK11 
CSF1R FLT3 KDR PIK3CA TP53 
CTNNB1 GNA11 KIT PTEN VHL 
 
3.3.5 Statistical methods 
In this thesis, the Kaplan-Meier method was used to generate survival curves and to calculate 
overall survival (OS) and disease-free survival (DFS) with the significance of the differences 
in survival between groups calculated using the Log-rank test. Hazard Ratios were calculated 
using uni- and multivariate Cox regression. Chi-square or Fisher’s exact test was used for 
calculating the significance of differences between categorical variables, while an 
independent t-test was applied for age differences between two groups. Calculations were 
performed using SPSS software (IBM, Armonk, NY, USA). Two-sided p-values were 
reported and p-values below 0.05 were considered as statistically significant. 
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4 RESULTS AND DISCUSSION 
 
4.1 HUMAN PAPILLOMAVIRUS AND P53 EXPRESSION IN CANCER OF 
UNKNOWN PRIMARY IN THE HEAD AND NECK REGION IN RELATION 
TO CLINICAL OUTCOME. (PAPER I) 
Aim 
In Paper I we aimed to examine the prevalence of HPV DNA in HNCUP, and whether HPV 
DNA and/or p16-status as well as p53-expression correlated to clinical outcome. 
Material and methods in brief 
Fifty lymph node metastases from patients diagnosed with HNCUP at the Karolinska 
University Hospital between 2000 and 2007 were analysed for HPV DNA, using a bead-
based assay and for p16- and p53-expression using immunohistochemistry, see Paper I for 
details. 
Main results 
HPV DNA was detected in 40% of the cases. Patients with HPV DNA-positive HNCUP had 
significantly better 5-year overall survival (OS) compared to patients with HPV DNA-
negative HNCUP (80.0% vs. 36.7%, p = 0.004). Similarly, p16-positive HNCUP had 
significantly better 5-year OS than p16-negative HNCUP (76.2% vs. 37.9%, p = 0.007) and 
HPV DNA+/p16+ HNCUP had significantly better outcome compared to HNCUP that were 
either HPV DNA or p16-negative (77.8% vs. 40.6% 5-year OS, p = 0.017). Having 
absent/intermediary-low p53-expression in the tumour tissue correlated to a better 5-year OS 
as compared to having a tumour with high p53-expression (69% vs. 14%, p < 0.001). 
Discussion 
That HPV DNA was found in HNCUP was expected since some HNCUP likely originates 
from HPV-positive TSCC/BOTSCC, however the proportion of HPV-positive cases had not 
been examined in this region before. In a recent systematic review on HPV-prevalence in 
HNCUP, our study had the highest proportion HPV+/p16+ cases among “true definite” 
HNCUP (Boscolo-Rizzo et al., 2015). This could be explained by that Sweden has a larger 
proportion HPV-positive TSCC/BOTSCC than many other countries (Näsman et al., 2015; 
Rietbergen et al., 2013; Tahtali et al., 2013). In addition, HPV DNA and overexpression of 
p16 correlated to a high degree, as has been shown for TSCC/BOTSCC (Ndiaye et al., 2014). 
Furthermore, to our knowledge, we showed for the first time that HPV DNA and 
overexpression of p16 are favourable prognostic factors in a “true definite” HNCUP setting. 
Previous studies on the subject either failed to reach significance (Compton et al., 2011; 
Tribius et al., 2012) or included patients were a primary tumour was found during 
examination or patients that would not be considered fully investigated today (e.g. not having 
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had tonsillectomy) (Park et al., 2012; Vent et al., 2013). Subsequently, others and we have 
confirmed that HPV DNA and/or p16 overexpression are favourable prognostic factors in 
HNCUP (Axelsson et al., 2017; Dixon et al., 2016; Jensen et al., 2014; Keller et al., 2014; 
Schroeder et al., 2017; Paper II). Thus, accumulating evidence suggests that HPV status is of 
prognostic importance not in only in TSCC/BOTSCC, but in HNCUP as well, which further 
strengthens the thesis that HPV-positive HNCUP originates from HPV-positive 
TSCC/BOTSCC.  
In this study, p53 expression was analysed by IHC, and as mentioned above, p53 is often 
degraded and rarely mutated in HPV-positive cancers, while it is often mutated in many other 
types of cancer, and then often correlated to poor prognosis (Yemelyanova et al., 2011). It is 
therefore not surprising that HNCUP with low p53-expression in this study had better 
prognosis than HNCUP with high p53-expression. However, unexpectedly, only a trend and 
not a statistically significant correlation between HPV-status and p53-expression was 
observed (p = 0.118). Furthermore, p53 was an even better prognostic marker than HPV in 
this study indicating that it may have an independent prognostic effect in HNCUP, regardless 
of HPV-status and that these markers could potentially be used together. HPV-positive 
HNCUP with low p53 expression showed a tendency towards having the best prognosis and 
HPV-negative HNCUP with high p53 expression having the worst, but the number of 
patients was limited and further studies would be of importance. One such study has since 
been published (Yildirim et al., 2017) showing statistically significant worse 2-year tumour 
specific survival (TSS) in multivariate analysis for p16 negative/p53 positive HNCUP 
compared to all other p16/p53 combinations grouped together (defining p53-positive as 
>10% of tumour cells stained). Yildirim et al. (2017) did however not find any significant 
differences on TSS between p16-negative and p16-positive HNCUP, or between p53-
negative and p53-positive HNCUP alone. However, this is another small, retrospective study 
and it would be most interesting to see results from a larger, prospective study on this subject.  
Conclusion 
Our data suggest that HPV-status should be investigated during the diagnostic work-up of 
HNCUP, since it provides valuable prognostic information and since a finding of HPV could 
steer further diagnostic procedures and potentially treatment towards the oropharynx. 
Moreover, patients with HPV-positive HNCUP could possibly receive less treatment than 
today, e.g. by omitting neck dissection, in analogy to the de-escalation of treatment proposed 
for HPV-positive TSCC/BOTSCC. Today, the work by us and others have led e.g. to that 
HPV and p16-status are now listed as “essential biomarkers” for the investigation of HNCUP 
in the UICC Manual of Clinical Oncology (O’Sullivan et al., 2015) and that according to the 
guidelines from the College of American Pathologists, HPV-testing should be performed in a 
SCC of unknown primary, if it is located in a cervical upper or mid jugular chain lymph node 
(Lewis et al., 2017). 
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4.2 VALIDATION OF HUMAN PAPILLOMAVIRUS AS A FAVOURABLE 
PROGNOSTIC MARKER AND ANALYSIS OF CD8+ TUMOUR-
INFILTRATING LYMPHOCYTES AND OTHER BIOMARKERS IN CANCER 
OF UNKNOWN PRIMARY IN THE HEAD AND NECK REGION. (PAPER II) 
Aim 
In Paper II we aimed to validate our findings regarding HPV DNA, p16 and p53 from Paper I 
in a separate HNCUP cohort, and also to analyse additional biomarkers: HPV16 mRNA, 
CD8+ tumour infiltrating lymphocytes (TILs) and HLA class I expression in relation to 
clinical outcome in the combined cohorts. 
Materials and methods in brief 
Nineteen HNCUP patients diagnosed at the Karolinska University Hospital between 2008 
and 2013 were used to study HPV DNA, p16 and p53. In addition, these 19 HNCUP together 
with the 50 HNCUP from Paper I were used for analysis of HPV16 mRNA, CD8+ TILs and 
HLA Class I expression. A bead-based multiplex assay was used for HPV DNA and mRNA 
analysis and IHC for the other markers (for more details see paper II). 
Main results 
Of the 19 HNCUP diagnosed 2008-2013, 63% were HPV DNA-positive. Patients with HPV 
DNA-positive HNCUP had significantly better 3-year OS and DFS compared to those with 
HPV-negative HNCUP (91.7% vs. 42.9%, p = 0.028 for OS and 100% vs. 66.7%, p = 0.045 
for DFS). Similar trends were observed when comparing HPV DNA+/p16+ HNCUP with 
HPV DNA-/p16- HNCUP and when comparing p16+ HNCUP with p16- HNCUP, however 
reaching significance only for OS in the former comparison. In the entire 2000-2013 cohort, 
HPV mRNA evaluation was possible in 86% of the HPV16 DNA-positive cases, of which 
92% were positive for HPV16 E6 and E7 mRNA. HNCUP in the three quartiles with the 
highest numbers of CD8+ TILs had significantly better 3-year OS and DFS compared to 
HNCUP in the quartile with the lowest number of CD8+ TILs. However, when dividing the 
cohort according to HPV-status comparing quartiles in the same manner, significance was 
reached only for 3-year DFS among patients with HPV-negative HNCUP. No significant 
differences in OS or DFS were observed when comparing absent/weak vs. high HLA Class I 
expression.  
Discussion 
Despite only 19 patients in the 2008-2013 cohort, we managed to validate HPV DNA as a 
favourable prognostic factor in HNCUP. This shows the profound effect HPV-positive status 
has on clinical outcome. Remarkably, 3-year DFS was 100% among patients with HPV 
DNA-positive HNCUP, although one must of course note that this group consisted of only 11 
patients. Moreover, considering the entire 2000-2013 cohort, resulting in one of the largest 
HNCUP cohorts to date, 3-year DFS was 90.6% and 3-year OS 84.8% among HPV-positive 
HNCUP, which is similar, possibly slightly better, than that observed for HPV-positive 
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TSCC/BOTSCC in Sweden (Attner et al., 2011; Lindqvist et al., 2007). Furthermore, our data 
are in the same range as in other recent large studies on survival in HNCUP (Jensen et al., 
2014; Schroeder et al., 2017). This further highlights the importance of testing for HPV in 
HNCUP. 
HPV16 E6 and/or E7 RNA have to our knowledge only been investigated in HNCUP in two 
small previous studies (Bishop et al., 2012; Bussu et al., 2014), finding HPV mRNA in 2 and 
10 cases respectively. In the 2000-2013 cohort, these data were confirmed this for the first 
time in a larger study, by the detection of HPV E6 and E7 mRNA in the great majority (92%) 
of the HPV16 DNA positive HNCUP. This is of importance, since a finding of HPV DNA in 
a tumour does not necessarily imply that it is caused by HPV, since it could also be due to a 
transient infection. The finding of HPV E6 and E7 mRNA, indicates transcriptionally active 
HPV, and supports the carcinogenic role of HPV in HNCUP. Subsequently, yet another 
study, has confirmed that HPV E6*I mRNA is indeed found in a proportion of HNCUP, 
further cementing HPVs role in the carcinogenesis of this disease (Schroeder at al., 2017). 
When not taking HPV-status into consideration, we found that HNCUP with very few CD8+ 
TILs, indicating an insufficient immune response to the tumour, had poor prognosis, which is 
in line with what has been shown before in a variety of cancer types, including ovarian-, and 
colorectal cancer as well as TSCC/BOTSCC (Galon et al., 2006; Nordfors et al., 2014; Sato 
et al., 2005). However, having a high number of CD8+ TILs correlated to being HPV 
DNA+/p16+, not surprising giving the viral component of the disease, making it difficult to 
draw any conclusion regarding the separate effect of the lack of CD8+ TILs. Notably, when 
we divided the cohort according to HPV-status we did not find a prognostic impact of the 
number of TILs in the HPV-positive group, as previously seen in HPV+ TSCC/BOTSCC 
(Nordfors et al., 2014). This could partly be due to the excellent prognosis among HPV+ 
HNCUP patients, with very few events and thus requiring a large cohort to show a 
statistically significant difference. We conclude that in order to investigate the possibility to 
use CD8+ TIL counts as a prognostic factor in conjunction to HPV-status in HNCUP, larger, 
preferably multicentre, studies need to be performed. 
The Dalianis group have previously showed that in HPV-positive TSCC/BOTSCC, having 
absent/weak HLA class I expression, somewhat counter intuitive, conferred a survival benefit 
as compared to having a high degree of HLA class I expression (Näsman et al., 2013). In this 
study however, absent/weak HLA class I expression was not correlated to clinical outcome in 
any group. This could be due the small cohort and few events, but it could of course also be 
due to that HNCUP differs from TSCC/BOTSCC in this aspect. It would not be surprising if 
HPV-positive HNCUP differs from HPV-positive TSCC/BOTSCC in some aspects, since we 
are comparing metastases to primary tumours. This is also emphasized by some data in Paper 
III. 
In the 2008-2013 cohort, having absent/low p53 expression correlated to HPV DNA-positive 
status. Given this and the fact that the cohort consisted of only 19 patients with very few 
events, a separate role of p53 expression on survival was not pursued. Likewise, the effect on 
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prognosis of a lack of HPV E2 mRNA, previously showed to be a negative prognostic factor 
in HPV-positive TSCC/BOTSCC (Ramqvist et al., 2015), could not be investigated, since 
only three HPV16 DNA positive HNCUP lacked HPV16 E2 mRNA. 
Conclusion 
The obtained data further strengthen the role of HPV as an important prognostic factor in 
HNCUP and our emphasis on that investigation of HPV-status should be part of the 
diagnostic work-up in HNCUP (see also the discussion for Paper I). Moreover, our data 
further reinforce the thesis that HPV-positive HNCUP arises from HPV-positive 
TSCC/BOTSCC, since both display transcriptionally active HPV (as determined by HPV E6 
and E7 expression) and exhibit an excellent clinical outcome. This further highlights the 
potential of HPV-positive status to influence treatment. However, to disclose other prognostic 
biomarkers possible to use together with HPV-positive status to further improve identification 
of patients with an excellent outcome, larger cohorts will have to be investigated. Due to the 
rareness of HPV-positive HNCUP and its excellent prognosis, multicentre studies would be 
preferable. 
 
4.3 TARGETED SEQUENCING OF TONSILLAR AND BASE OF TONGUE 
CANCER AND HUMAN PAPILLOMAVIRUS POSITIVE UNKNOWN 
PRIMARY OF THE HEAD AND NECK REVEALS PROGNOSTIC EFFECTS 
OF MUTATED FGFR3. (PAPER III) 
Aim 
In Paper III we aimed to find prognostic markers in TSCC/BOTSCC, as well as to compare 
the presence of hot spot mutations in cancer related genes in HPV-positive TSCC/BOTSCC, 
HPV-negative TSCC/BOTSCC and HPV-positive HNCUP using targeted next generation 
sequencing (NGS).  
Material and Methods in brief 
Targeted NGS was performed on DNA from 348 TSCC/BOTSCC diagnosed 2000-2011 and 
the 20 HPV DNA-positive HNCUP from Paper I. The Ion AmpliSeq Cancer Hotspot Panel 
v2, covering mutations in frequently altered regions in 50 genes commonly mutated in 
cancer, was used on the Ion Proton sequencing platform (see Paper III for details). 
Main results 
HPV-positive TSCC/BOTSCC contained significantly fewer mutations/tumour than HPV-
negative TSCC/BOTSCC (0.92 vs. 1.68), with HPV-positive HNCUP presenting an 
intermediate of 1.32 mutations/tumour. The most commonly mutated genes were in HPV-
positive TSCC/BOTSCC: PIK3CA (20.1%), TP53 (9.3%) and FGFR3 (7.2%) and in HPV-
negative TSCC/BOTSCC: TP53 (63.8%), PIK3CA (6.4%) and IDH2 (6.4%). In HPV-
positive HNCUP, TP53 (26.3%), CDKN2A (15.8%) and PIK3CA (15.8%) were the most 
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frequently mutated genes. TP53, IDH2 and NOTCH1 were significantly more often mutated 
in HPV-negative TSCC/BOTSCC compared to in HPV-positive TSCC/BOTSCC, while 
PIK3CA was more often mutated in HPV-positive TSCC/BOTSCC than its negative 
counterpart. For HPV-positive HNCUP, TP53 was significantly more often mutated than in 
HPV-positive TSCC/BOTSCC, but significantly less often mutated than in HPV-negative 
TSCC/BOTSCC.  
Patients with HPV-positive TSCC/BOTSCC had significantly worse 3-year DFS if they had a 
mutation in FGFR3 compared to if they had wild type FGFR3 (p = 0.002). The most common 
FGFR3 variant was S249C (11 of 19 cases). When comparing this variant to patients with 
other FGFR3 variants or wild type FGFR3, patients with the S249C variant had a 
significantly worse 3-year DFS (p = 0.009). One FGFR3 mutation was found for HPV-
negative TSCC/BOTSCC, while no FGFR3 mutations were found for HPV-positive 
HNCUP. 
Discussion 
That PIK3CA was the most frequently mutated gene in HPV-positive TSCC/BOTSCC, and 
that TP53 was the most commonly mutated gene in HPV-negative TSCC/BOTSCC and more 
often mutated there than in HPV-positive TSCC/BOTSCC are in line with previous studies 
(Cancer Genome Atlas Network, 2015; Chung et al., 2015; Lechner et al., 2013; Seiwert et 
al., 2015; Tinhofer et al., 2016). 
Notably, FGFR3 mutations, including the S249C variant, have also been shown in HNSCC, 
but to our knowledge this is the first time they have been correlated to a worse prognosis in 
HPV-positive TSCC/BOTSCC (Chung et al., 2015; Lechner et al., 2013; Seiwert et al., 2015; 
Tinhofer et al., 2016). Interestingly, FGFR3 are potentially targetable by drugs, making 
FGFR3 an intriguing subject for further studies (Gust et al., 2013; Miyake et al., 2010). 
To our knowledge, this is the very first study investigating mutations in HPV-positive 
HNCUP. Since the cohort consisted of only 19 patients, the results need, of course, to be 
interpreted with some caution, but at least this study offers a first glimpse into the mutational 
landscape of HPV-positive HNCUP. Interestingly, when analysing our data, HPV-positive 
HNCUP appears to be an intermediate group compared to HPV-positive and HPV-negative 
TSCC/BOTSCC in some features.  
The mutation rate per tumour (1.32), was as mentioned above, in between HPV-positive 
TSCC/BOTSCC (0.92) and HPV-negative TSCC/BOTSCC (1.68). Likewise, the mutation 
rate of TP53 was higher in HPV-positive HNCUP (26.3%) than in HPV-positive 
TSCC/BOTSCC (9.3%), but much lower than in HPV- negative TSCC/BOTSCC (63.8%). 
However, HPV-positive HNCUP was more similar to HPV-positive TSCC/BOTSCC than to 
HPV-negative TSCC/BOTSCC with regard to some other characteristics. More specifically, 
47.4% of the HPV-positive HNCUP contained variants, similar to 48.7% in HPV-positive 
TSCC/BOTSCC, both much less than the 74.5% variants observed in HPV-negative 
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TSCC/BOTSCC. Furthermore, HPV-positive HNCUP exhibited similar mutation rate of 
PIK3CA as HPV-positive TSCC/BOTSCC (15.8% vs. 20.1% respectively), which is more 
than in HPV-negative TSCC/BOTSCC (6.4%). However, HPV-positive HNCUP exhibited a 
higher mutational rate of CDKN2A than both HPV-positive and HPV-negative 
TSCC/BOTSCC (15.8% vs. 4.3% vs. 4.3% respectively).  
There are limitations to this study, and a major one is that the number of variants noted were 
very few, e.g. only three HPV-positive HNCUP had PIK3CA or CDKN2A variants 
respectively, and it is therefore difficult to draw any conclusion of these findings as they need 
to be verified in larger cohorts. Furthermore, in this study, it is worth pointing out that only 
50 genes were examined, and in these 50 genes, only the most commonly mutated regions 
were covered, i.e. hot spots. Thus, certain mutations might have been missed. However, 
carrying out whole genome (or whole exome) sequencing on such a large cohort would have 
required significantly more resources (e.g. financial and bioinformatical) than available. 
Our data show some similarities between HPV-positive HNCUP and HPV-positive TSCC/ 
BOTSCC and strengthen the thesis that HPV-positive HNCUP originates from HPV-positive 
TSCC/BOTSCC. In other aspects however, there are differences, which is to be expected, 
since we in this study compare metastases with primary tumours (see also Paper II). Another 
potential reason for the differences observed between HPV-positive HNCUP and HPV-
positive TSCC/BOTSCC could be the higher frequency of smokers in the HPV-positive 
HNCUP cohort than in the HPV-positive TSCC/BOTSCC cohort, since smoking is known to 
cause mutations in e.g. TP53 (Brennan et al., 1995). It could therefore potentially be of 
interest to compare HPV-positive HNCUP to metastases from HPV-positive 
TSCC/BOTSCC, with a similar proportion of smokers between the two groups to disclose 
possible similarities and differences. Sequencing HPV-negative HNCUP and metastases from 
HPV-negative TSCC/BOTSCC could add further value to such a study, exploring the biology 
of HNCUP. 
Conclusion 
Our study largely confirms the genetic landscape described before for HPV-positive and 
HPV-negative TSCC/BOTSCC. Notably, we found that FGFR3 mutations (especially the 
S249C variant) as promising prognostic factors in HPV-positive TSCC/BOTSCC, predicting 
worse outcome. Since FGFR3 is a potential drug target, this could be of importance for 
implementing personalised medicine for HPV-positive TSCC/BOTSCC in the future and thus 
warrants further studies. Moreover, this study offers a first glimpse into the genetics of HPV-
positive HNCUP with TP53, PIK3CA and CDKN2A as the most frequently mutated genes. 
HPV-positive HNCUP exhibited several genetic similarities to HPV-positive 
TSCC/BOTSCC, but also a few differences. Whether HPV-positive HNCUP should be 
considered as metastases from HPV-positive TSCC/BOTSCC with additional modifications 
needs to be studied further in larger cohorts, although data from Papers I-III suggest that this 
is the case. 
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4.4 HUMAN PAPILLOMAVIRUS DNA DETECTION IN FINE-NEEDLE 
ASPIRATES AS INDICATOR OF HUMAN PAPILLOMAVIRUS-POSITIVE 
OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: A PROSPECTIVE 
STUDY. (PAPER IV) 
Aim 
In Paper IV we aimed to investigate whether HPV DNA and HPV16 mRNA detection in 
fine-needle aspirate cytology (FNAC) was reliable and whether HPV detection in FNAC 
from a neck mass could prospectively predict an HPV-positive TSCC/BOTSCC as the final 
diagnosis.  
Material and methods in brief 
FNACs from 66 patients with enlarged neck masses were prospectively analysed for HPV 
DNA and HPV16 mRNA (if HPV16 positive) using a bead-based multiplex assay. Results 
were correlated to final diagnosis and HPV-status from histopathological specimens (if 
available). 
Main results 
All 66 FNACs contained enough material for DNA analysis and 17/66 FNACs contained 
HPV16 DNA. No other HPV types were detected. For all 17 patients with an HPV-positive 
FNAC, the final diagnosis was an HPV-positive TSCC or BOTSCC. Three FNACs from 
OPSCC were HPV DNA-negative – two TSCC and one OPSCC originating from the back 
wall of the oropharynx. All 17 malignant non-OPSCC cases were HPV DNA negative and 
this was true also for the 29 cases of benign conditions, of which 18 were branchial cleft 
cysts. When available, HPV status of corresponding histopathological specimens showed 
perfect concordance to the HPV status from the FNACs. HPV16 E7 and E6*I mRNA were 
detected in all 7 HPV16 DNA-positive samples that were possible to evaluate for mRNA. 
Discussion 
In this study, we demonstrate that a finding of HPV DNA in FNACs prospectively collected 
from enlarged neck masses could predict an HPV-positive TSCC/BOTSCC as the final 
diagnosis. Notably, the specificity and sensitivity for predicting an HPV+ 
OPSCC/TSCC/BOTSCC was 100% and the presence of HPV DNA was not observed in any 
other malignant or benign conditions. These data are to our knowledge, the first of their kind 
in a prospective setup including an unselected cohort of patients with both malignant and 
benign conditions. In a larger study, it is possible that the specificity and the sensitivity would 
not have been 100% since a small proportion of HNSCC other than OPSCC are also HPV-
positive (Plummer et al., 2016). Furthermore, it has been shown when evaluating DNA from 
FNACs on glass slides with low cellularity that it is not always possible to evaluate the 
presence of HPV DNA optimally (Channir et al., 2016). Nevertheless, our data are in line 
with previous studies, generally showing that HPV-detection in FNAC is feasible and that a 
finding of HPV DNA indicates an OPSCC with a very good specificity of 90-100% 
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(Baldassarri et al., 2015; Barwad et al., 2012; Begum et al., 2007; Bishop et al., 2012; Guo et 
al., 2014; Jannapureddy et al., 2010; Kerr et al., 2014; Lastra et al., 2013; Smith et al., 2014; 
Solomides et al., 2012; Umudum et al., 2005; Zhang et al., 2008).  
Importantly though, our study included not only verified HNSCC, but benign conditions as 
well. As mentioned above, if HPV is found in a cervical lymph node metastasis it is assumed 
to be an HPV-positive OPSCC. However, whether HPV can be found in other, benign, 
conditions causing neck masses has not been extensively studied. Should this be the case then 
this could potentially lead to overtreatment of these benign conditions if they indeed harbour 
HPV. In this study, all 29 patients with benign conditions had HPV-negative FNACs, 
including the 18 branchial cleft cysts (BCC). The latter is a condition of special interest since 
BCCs are sometimes very difficult to distinguish from cystic metastases from HPV-positive 
OPSCC (see introduction). BCCs are furthermore sometimes associated with fistulas 
originating in the tonsils – a possible point of entry to the cyst for viruses. However, in this 
study, all BCCs were HPV-negative, although, of course, 18 cases are too few to conclude 
that BCCs can never be HPV-positive and this should be, and has in fact, been investigated 
further by us.  
For optimal diagnosis of an HPV-positive TSCC/BOTSCC, we and others, have suggested 
that the presence of an HPV DNA-positive result should be in association with p16 
overexpression (Näsman et al., 2009; Smeets et al., 2007). This combination is close to the 
golden standard, which is the possibility to assess for HPV mRNA. The assessment of p16 
expression is problematic in FNACs since the material and cellularity of the samples is such 
that it is suboptimal for such an investigation and the result difficult to interpret. Instead, we 
here analysed for the presence of HPV16 mRNA. It was possible to obtain mRNA from 7 of 
the 16 tested HPV16 DNA-positive samples and all were HPV mRNA positive indicating an 
active HPV infection. 
It is possible that the optimal assessment of HPV status in FNACs would be to assess for 
HPV mRNA, but presently, we do not know how efficiently this can be done and whether it 
is practical in clinical use. As mentioned previously, RNA is much less stable than DNA and 
requires optimal handling of the samples, e.g. ideally fresh frozen specimens or storage in 
RNA-conserving solutions. In this study we did not have a method optimized for RNA 
detection, but still managed to detect HPV mRNA in all 7/16 tested HPV DNA-positive 
samples, where RNA detection was possible, indicating that HPV mRNA detection in FNAC 
is indeed conceivable. This should be investigated further in studies with protocols optimized 
for RNA-detection. 
Conclusion 
HPV DNA detection in FNAC from neck masses was feasible and in this study the presence 
of HPV DNA in FNAC indicated an HPV-positive TSCC/BOTSCC as the final diagnosis 
with a specificity and sensitivity of 100%. Furthermore, HPV DNA was not found in any 
other malignant conditions than HPV-positive TSCC/BOTSCC or in benign conditions, 
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including BCCs. The data therefore indicates that the presence of HPV DNA should be 
investigated using FNAC in patients with neck masses of unknown origins. This could be 
helpful for an early diagnosis of an HPV-positive TSCC/BOTSCC, as well as potentially for 
distinguishing between cystic metastases and benign cysts, e.g. BCCs. HPV mRNA detection 
in FNAC should be studied further using protocols optimized for mRNA detection. 
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5 CONCLUSIONS 
 
• In Sweden, a large proportion of HNCUP is HPV DNA-positive and most HPV16 
DNA-positive HNCUP samples express HPV16 mRNA (Papers I and II) 
 
• Patients with HPV-positive HNCUP have a better clinical outcome than patients with 
HPV-negative HNCUP (Paper I and II) 
 
• CD8+ TILs and p53-expression are interesting biomarkers to use in combination with 
HPV-status, but need to be studied further in larger cohorts (Papers I and II) 
 
• Investigation of HPV-status should be part of the diagnostic work-up of an HNCUP 
(Papers I and II) 
 
• Patients with HPV-positive TSCC/BOTSCC with a mutation in the FGFR3 gene have 
a worse clinical outcome compared to HPV-positive TSCC/BOTSCC with wild type 
FGFR3 (Paper III) 
 
• In HPV-positive HNCUP, TP53, PIK3CA and CDKN2A were the most frequently 
mutated genes (Paper III) 
 
• HPV-positive HNCUP share many similarities with regard to prognostic biomarkers 
with HPV-positive TSCC/BOTSCC, but there also differences (Papers I – III) 
 
• HPV DNA-detection in FNAC is feasible and detection of HPV DNA in a FNAC 
from a neck mass of unknown origin is highly indicative of an HPV-positive 
TSCC/BOTSCC (Paper IV) 
 
• HPV DNA was not found in FNAC from other malignancies than HPV-positive 
TSCC/BOTSCC or in benign conditions, including BCCs (Paper IV) 
 
• HPV mRNA detection in FNAC is promising but needs to be studied further (Paper 
IV) 
 
• Investigation of HPV DNA-status using FNAC is useful in the diagnostic work up of 
patients with neck masses of unknown origins (Paper IV). 
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6 FUTURE PERSPECTIVES 
 
When discussing future perspectives related to HPV, first of all the prophylactic HPV-
vaccines must be mentioned. HPV-vaccines have been shown to be effective, and safe, in 
preventing cancer of the uterine cervix (FUTURE II Study Group, 2007; Villa et al., 2005; 
Villa et al., 2006). Presently, no direct evidence exists that the vaccine is able to prevent 
HPV-positive TSCC/BOTSCC/HNCUP, and there are no pre-stages either one can monitor 
as in cervical cancer. Therefore, it will take some decades before one can observe the effects 
on HPV-positive TSCC/BOTSCC/HNCUP, since it takes a very long time to develop.  
Nonetheless, since HPV16 is the cause of >80% of HPV-positive TSCC/BOTSCC/HNCUP 
and HPV16 is covered in all available HPV-vaccines it is highly plausible that the vaccine 
will work in preventing HPV-positive TSCC/BOTSCC/HNCUP as well. Furthermore, 
studies have already showed a decline in the prevalence of HPV16 in the oral cavity of 
vaccinated individuals, giving circumstantial evidence for an effect on HPV-positive 
TSCC/BOTSCC/HNCUP (Chaturvedi et al., 2018; Grün et al., 2015). It is thus conceivable 
that we in the future (in 20-30+ years) will see a decline in the incidence of HPV-positive 
TSCC/BOTSCC/HNCUP. However, to achieve this, it is of utmost importance that the 
coverage of the vaccine is as high as possible. In Sweden today, HPV vaccine coverage is 
fairly good, at around 80% among young girls (Folkhälsomyndigheten, 2016). It is important 
to keep it this way and not like in Denmark, lose participants in the vaccination program due 
to e.g. unwarranted fear of side effects (Brinth et al., 2015; European Medicines Agency, 
2015). Here, as health care professionals and researchers, we have an important task to 
inform patients and the public about the benefits and safety of the vaccine. Furthermore, as 
mentioned previously, HPV causes cancer not only in women, but also in men, e.g. ~80% of 
HPV-positive TSCC/BOTSCC as well as anal- and penile cancers (Plummer et al., 2016). It 
is thus most unfortunate that we in Sweden do not vaccinate boys and it is imperative that we 
in the future include boys in the vaccination program. On a global scale, HPV related cancers 
are more prevalent in the developing world than in the developed world (Plummer et al., 
2016). It is thus vital that the vaccines are made available, and affordable, to the public also in 
these parts of the world. 
Clearly, the advent of the HPV-vaccine has the potential to decrease the incidence of HPV-
positive TSCC/BOTSCC/HNCUP substantially. However, vaccination coverage will likely 
never be 100%, even if we start to vaccinate boys. Moreover, it likely takes 20-30 years to 
develop TSCC/BOTSCC. For this reason, HPV-positive TSCC/BOTSCC/ HNCUP will not 
be eradicated in the near future and there is still a need for improved therapy for e.g. HPV-
positive HNCUP for a long period of time. As mentioned, others and we and have shown that 
HPV-positive HNCUP has a better clinical outcome than HPV-negative HNCUP. The 
question for the future however, is if this should influence treatment or not. For HPV-positive 
OPSCC there are trials investigating de-escalation of treatment on going (Mirghani et al., 
2015). The problem with HNCUP is that it is such a rare entity that randomized controlled 
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trials (RCT) will be very difficult to perform. Indeed, very few RCT’s have yet been 
performed comparing treatments for HNCUP, while retrospective studies have shown very 
little difference in clinical outcome when comparing different treatments, e.g. RT alone vs. 
surgery alone vs. combination treatment (Balaker et al., 2012). However, these studies have 
not taken HPV-status into account, and such studies are very much needed and are possibly 
best performed in collaboration with other centres in order to achieve larger patient numbers 
for adequate evaluation. Today, it is still very much up to each centre, or even each physician, 
to decide which treatment is the best for each patient. While we await further studies, HPV-
status could be another tool when selecting treatment. Indeed, at the Karolinska University 
Hospital more recently, HPV-status has been implemented as a parameter for selecting 
treatment for HNCUP, e.g. now some patients with HPV-positive HNCUP do not undergo 
neck dissection and receive RT only (Vårdprogram – Okänd primär, 2015). Follow-up 
studies on the outcome of these patients would be very interesting. 
Testing HPV-status in neck masses of unknown origin using FNAC is a very promising 
diagnostic tool for the future. As FNAC is already part of the diagnostic work-up of these 
patients, adding an HPV-test of the aspirate could be easily implemented and is something 
that is infrequently done today at the Karolinska University Hospital (See Paper IV). This 
would give the clinician early information and, if HPV-positive, could steer further diagnostic 
procedures towards the oropharynx. Analysing HPV-status in FNAC may be particularly 
useful for HNCUP, where no primary tumour can be analysed and especially valuable if 
patients are treated with RT only, where sparse histopathological specimens may be 
available. Future studies are needed to examine if HPV mRNA detection in FNAC could be 
useful and whether HPV testing is valuable for the diagnostic work up of BCCs. 
To conclude, with the advent of the HPV-vaccines, with improved diagnostic tools for HPV-
related HNSCC and also with recent, encouraging results for immunotherapy in HNSCC 
(Ferris et al., 2016), it is indeed an exciting time for HPV-related TSCC/BOTSCC/HNCUP 
research! My hope is that the research carried out by us, in this thesis and elsewhere, will be 
beneficial for people with TSCC/BOTSCC/HNCUP in the future. By contributing in a small 
way, together with research done by others, I hope the diagnostics and therapy will be 
improved, leading to better survival, less side effects and a better quality of life. 
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